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Summary
The U. S. Selected Practice Recommendations for Contraceptive Use 2013 (U.S. SPR), comprises recommendations that 
address a select group of common, yet sometimes controversial or complex, issues regarding initiation and use of specific contraceptive 
methods. These recommendations are a companion document to the previously published CDC recommendations U.S. Medical 
Eligibility Criteria for Contraceptive Use, 2010 (U.S. MEC). U.S. MEC describes who can use various methods of contraception, 
whereas this report describes how contraceptive methods can be used. CDC based these U.S. SPR guidelines on the global family 
planning guidance provided by the World Health Organization (WHO). Although many of the recommendations are the same 
as those provided by WHO, they have been adapted to be more specific to U.S. practices or have been modified because of new 
evidence. In addition, four new topics are addressed, including the effectiveness of female sterilization, extended use of combined 
hormonal methods and bleeding problems, starting regular contraception after use of emergency contraception, and determining 
when contraception is no longer needed. The recommendations in this report are intended to serve as a source of clinical guidance 
for health-care providers; health-care providers should always consider the individual clinical circumstances of each person seeking 
family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. 
Persons should seek advice from their health-care providers when considering family planning options.
Introduction
Unintended pregnancy rates remain high in the United 
States; approximately 50% of all pregnancies are unintended, 
with higher proportions among adolescent and young women, 
women who are racial/ethnic minorities, and women with lower 
levels of education and income (1). Unintended pregnancies 
increase the risk for poor maternal and infant outcomes (2) 
and in 2002, resulted in $5 billion in direct medical costs in the 
United States (3). Approximately half of unintended pregnancies 
are among women who were not using contraception at the 
time they became pregnant; the other half are among women 
who became pregnant despite reported use of contraception 
(4). Therefore, strategies to prevent unintended pregnancy 
include assisting women at risk for unintended pregnancy and 
their partners with choosing appropriate contraceptive methods 
and helping women use methods correctly and consistently 
to prevent pregnancy. In 2010, CDC first adapted global 
guidance from the World Health Organization (WHO) to 
help health-care providers counsel women, men, and couples 
about contraceptive method choice. The U.S. Medical Eligibility 
Criteria for Contraceptive Use, 2010 (U.S. MEC), focuses on who 
can safely use specific methods of contraception and provides 
recommendations for the safety of contraceptive methods for 
women with various medical conditions (e.g., hypertension and 
diabetes) and characteristics (e.g., age, parity, and smoking status) 
(Appendix A) (5). The recommendations in this new guide, U.S. 
Selected Practice Recommendations for Contraceptive Use, 2013 
(U.S. SPR), focuses on how contraceptive methods can be used 
and provides recommendations on optimal use of contraceptive 
methods for persons of all ages, including adolescents.
During the past 15 years, CDC has contributed to the 
development and updating of the WHO global family planning 
guidance. CDC has supported WHO by coordinating the 
identification, critical appraisal, and synthesis of the scientific 
evidence on which the WHO guidance is based. In 2002, 
WHO published the first edition of the Selected Practice 
Recommendations for Contraceptive Use (WHO SPR), which 
presented evidence-based global guidance on how to use 
contraceptive methods safely and effectively once they are 
deemed to be medically appropriate. Since then, WHO has 
regularly updated its guidance on the basis of new evidence, 
and the document is now in its second edition (6), with an 
additional update in 2008 (7). The WHO global guidance is 
not intended for use directly by health-care providers; rather, 
WHO intends for the guidance to be used by local or national 
policy makers, family planning program managers, and the 
The material in this report originated in the National Center for 
Chronic Disease Prevention and Health Promotion, Ursula Bauer, 
PhD, Director; Division of Reproductive Health, Wanda Barfield, 
MD, Director.
Corresponding preparer: Kathryn M. Curtis, PhD, Division of 
Reproductive Health. Telephone: 770-488-5200; E-mail: kmc6@cdc.gov.
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scientific community as a reference when they develop family 
planning guidance at the country or program level (6). For 
example, the United Kingdom adapted WHO SPR and in 
2002 published the U.K. Selected Practice Recommendations 
for Contraceptive Use for use by U.K. health-care providers (8).
CDC initiated a formal adaptation process to create U.S. 
SPR, using both the second edition of WHO SPR (6) and the 
2008 update (7) as the basis for the U.S. version. Although 
much of the guidance is the same as the WHO guidance, 
the recommendations are specific to U.S. family planning 
practice. In addition, guidance on contraceptive methods not 
available in the United States has been removed, and four 
new topics for guidance have been added (the effectiveness 
of female sterilization, extended use of combined hormonal 
methods and bleeding problems, starting regular contraception 
after use of emergency contraception, and determining when 
contraception is no longer needed). This document contains 
recommendations for health-care providers for the safe and 
effective use of contraceptive methods and addresses provision of 
contraceptive methods and management of side effects and other 
problems with contraceptive method use. Although the term 
woman is used throughout this report, these recommendations 
refer to all females of reproductive age, including adolescents. 
Adolescents are identified throughout this document as a special 
population that might benefit from more frequent follow-up. 
These recommendations are meant to serve as a source of 
clinical guidance for health-care providers; health-care providers 
should always consider the individual clinical circumstances 
of each person seeking family planning services. This report is 
not intended to be a substitute for professional medical advice 
for individual patients; persons should seek advice from their 
health-care providers when considering family planning options.
Methods
CDC initiated a process to adapt WHO SPR for the 
United States. This adaptation process included four steps: 
1) determining the scope of and process for the adaptation, 
including an October 2010 meeting in which individual 
feedback was solicited from a small group of partners and 
experts; 2) preparing the systematic reviews of the evidence 
during October 2010–September 2011 to be used for the 
adaptation, including peer review; 3) convening a larger 
meeting of experts in October 2011 to examine the evidence 
and receive input on the recommendations; and 4) finalizing 
recommendations by CDC.
During October 21–22, 2010, CDC convened a meeting of 10 
partners and U.S. family planning experts in Atlanta, Georgia, to 
discuss the scope of and process for a U.S. adaptation of WHO 
SPR. A list of participants is provided at the end of this report. 
CDC identified the specific WHO recommendations that might 
benefit from modification for the United States. Criteria used to 
modify the WHO recommendations included the availability of 
new scientific evidence or the context in which family planning 
services are provided in the United States. CDC also identified 
several WHO recommendations that needed additional specificity 
to be useful for U.S. health-care providers, as well as the need for 
additional recommendations not currently included in WHO 
SPR. In addition, the meeting members discussed removing 
recommendations that provide information about contraceptive 
methods that are not available in the United States.
Representatives from CDC and WHO conducted systematic 
reviews of the scientific evidence for each of the WHO 
recommendations being considered for adaptation and for each 
new topic being considered for addition to the guidance. The 
purpose of these systematic reviews was to identify evidence 
related to the common clinical challenges associated with the 
recommendations. When no direct evidence was available, 
indirect evidence and theoretical issues were considered. Standard 
guidelines were followed for reporting systematic reviews (9,10), 
and strength and quality of the evidence were graded using the 
system of the U.S. Preventive Services Task Force (11). Each 
complete systematic review was peer reviewed by two or three 
experts before its use in the adaptation process. Peer reviewers, 
who were identified from the list of persons scheduled to 
participate in the October 2011 meeting, were asked to comment 
on the search strategy, list of articles included in the reviews, and 
the summary of findings. The systematic reviews were finalized 
and provided to participants before the October 2011 meeting 
and were published in May 2013 (12–30).
During October 4–7, 2011, CDC convened a meeting in 
Atlanta, Georgia, of 36 experts who were invited to assist in 
guideline development and provide their perspective on the 
scientific evidence presented and the discussions on potential 
recommendations that followed. The group included obstetrician/
gynecologists, pediatricians, family physicians, nurse-midwives, 
nurse practitioners, epidemiologists, and others with research and 
clinical practice expertise in contraceptive safety, effectiveness, and 
management. All participants received all of the systematic reviews 
before the meeting. During the meeting, the evidence from the 
systematic review for each topic was presented, and participants 
discussed the evidence and the translation of the scientific evidence 
into recommendations that would meet the needs of U.S. health-
care providers. In particular, participants discussed whether and 
how the U.S. context might be different from the global context 
and whether these differences suggested any need for modifications 
to the global guidance. CDC gathered the input from the experts 
during the meeting and finalized the recommendations in this 
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report. The document was peer reviewed by meeting participants, 
who were asked to comment on specific issues that were raised 
during the meeting. Feedback also was received from an external 
review panel, composed of health-care providers who had not 
participated in the adaptation meetings. These providers were 
asked to provide comments on the accuracy, feasibility, and clarity 
of the recommendations, as well as to provide other comments. 
Areas of research that need additional investigation also were 
considered during the meeting (31).
How To Use This Document
The recommendations in this report are intended to 
help health-care providers address issues related to use of 
contraceptives, such as how to help a woman initiate use of a 
contraceptive method, which examinations and tests are needed 
before initiating use of a contraceptive method, what regular 
follow-up is needed, and how to address problems that often 
arise during use, including missed pills and side effects such as 
unscheduled bleeding. Each recommendation addresses what 
a woman or health-care provider can do in specific situations. 
For situations in which certain groups of women might be 
medically ineligible to follow the recommendations, comments 
and reference to U.S. MEC are provided (5). The full U.S. 
MEC recommendations and the evidence supporting those 
recommendations were published in 2010 (5).
The information in this document is organized by 
contraceptive method, and the methods generally are presented 
in order of effectiveness, from highest to lowest. However, the 
recommendations are not intended to provide guidance on 
every aspect of provision and management of contraceptive 
method use. Instead, they use the best available evidence 
to address specific issues regarding common, yet sometimes 
complex, clinical issues. Each contraceptive method section 
generally includes information about initiation of the method, 
regular follow-up, and management of problems with use (e.g., 
usage errors and side effects). Each section first provides the 
recommendation and then includes a comments and evidence 
section, which includes comments about the recommendations 
and a brief summary of the scientific evidence on which the 
recommendation is based.
Recommendations in this document are provided for 
permanent methods of contraception, such as vasectomy 
and female sterilization, as well as for reversible methods of 
contraception, including the copper-containing intrauterine 
device (Cu-IUD); levonorgestrel-releasing IUD (LNG-IUD); 
the etonogestrel implant; progestin-only injectables; progestin-
only pills (POPs); combined hormonal contraceptive methods 
that contain both estrogen and a progestin, including combined 
oral contraceptives (COCs), a transdermal contraceptive patch, 
and a vaginal contraceptive ring; and the standard days method 
(SDM). Recommendations also are provided for emergency 
use of the Cu-IUD and emergency contraceptive pills (ECPs).
For each contraceptive method, recommendations are provided 
on the timing for initiation of the method and indications for 
when and for how long additional contraception, or a back-up 
method, is needed. Many of these recommendations include 
guidance that a woman can start a contraceptive method at any 
time during her menstrual cycle if it is reasonably certain that 
the woman is not pregnant. Guidance for health-care providers 
on how to be reasonably certain that a woman is not pregnant 
is provided.
For each contraceptive method, recommendations include the 
examinations and tests needed before initiation of the method. 
These recommendations apply to persons who are presumed to 
be healthy. Those with known medical problems or other special 
conditions might need additional examinations or tests before 
being determined to be appropriate candidates for a particular 
method of contraception. U.S. MEC might be useful in such 
circumstances (5). Most women need no or very few examinations 
or tests before initiating a contraceptive method. The following 
classification system was developed by WHO and adopted by 
CDC to categorize the applicability of the various examinations 
or tests before initiation of contraceptive methods (6):
Class A:  These tests and examinations are essential and 
mandatory in all circumstances for safe and effective use of 
the contraceptive method.
Class B: These tests and examinations contribute substantially 
to safe and effective use, although implementation can be 
considered within the public health context, service context, or 
both. The risk for not performing an examination or test should 
be balanced against the benefits of making the contraceptive 
method available.
Class C: These tests and examinations do not contribute 
substantially to safe and effective use of the contraceptive method.
These classifications focus on the relation of the examinations 
or tests to safe initiation of a contraceptive method. They 
are not intended to address the appropriateness of these 
examinations or tests in other circumstances. For example, 
some of the examinations or tests that are not deemed necessary 
for safe and effective contraceptive use might be appropriate 
for good preventive health care or for diagnosing or assessing 
suspected medical conditions. Systematic reviews were 
conducted for several different types of examinations and tests 
to assess whether a screening test was associated with safe use 
of contraceptive methods. Because no single convention exists 
for screening panels for certain diseases, including diabetes, 
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lipid disorders, and liver diseases, the search strategies included 
broad terms for the tests and diseases of interest.
Summary charts and clinical algorithms that summarize 
the guidance for the various contraceptive methods have been 
developed for many of the recommendations, including when 
to start using specific contraceptive methods (Appendix B), 
examinations and tests needed before initiating the various 
contraceptive methods (Appendix C), routine follow-up after 
initiating contraception (Appendix D), management of bleeding 
irregularities (Appendix E), and management of IUDs when 
users are found to have pelvic inflammatory disease (PID) 
(Appendix F). These summaries might be helpful to health-care 
providers when managing family planning patients. Additional 
tools are available on the U.S. SPR website (http://www.cdc.
gov/reproductivehealth/UnintendedPregnancy/USSPR.htm).
Summary of Changes from WHO SPR
Much of the guidance in U.S. SPR is the same or very similar 
to the WHO SPR guidance. U.S. SPR includes new guidance 
on the use of the combined contraceptive patch and vaginal 
ring, as well as recommendations for four new topics:
•	 how	to	start	regular	contraception	after	taking	ECPs
•	 management	 of	 bleeding	 irregularities	 among	women	
using extended or continuous combined hormonal 
contraceptives (including pills, the patch, and the ring)
•	 when	a	woman	can	rely	on	female	sterilization	for	contraception
•	 when	a	woman	can	stop	using	contraceptives	and	not	be	
at risk for unintended pregnancy
Adaptations to the WHO SPR recommendations include 
1) changes to the length of the grace period for depot 
medroxyprogesterone acetate (DMPA) reinjection, 2) differences 
in some of the examinations and tests recommended before 
contraceptive method initiation, 3) differences in some of the 
recommendations for management of bleeding irregularities 
because of new data and drug availability in the United States, 
and 4) a modified missed pill algorithm to respond to concerns 
of the CDC expert group and other reviewers that simplified 
algorithms are preferable.
Contraceptive Method Choice
Many elements need to be considered individually by a 
woman, man, or couple when choosing the most appropriate 
contraceptive method. Some of these elements include 
safety, effectiveness, availability (including accessibility and 
affordability), and acceptability.
Contraceptive method effectiveness is critically important 
in minimizing the risk for unintended pregnancy, particularly 
among women for whom an unintended pregnancy would 
pose additional health risks. The effectiveness of contraceptive 
methods depends both on the inherent effectiveness of the 
method itself and on how consistently and correctly it is used 
(Table 1). Both consistent and correct use can vary greatly 
with characteristics such as age, income, desire to prevent 
or delay pregnancy, and culture. Methods that depend on 
consistent and correct use by clients have a wide range of 
effectiveness between typical and perfect users. IUDs and 
implants are considered long-acting, reversible contraception 
(LARC); these methods are highly effective because they do not 
depend on regular compliance from the user. LARC methods 
are appropriate for most women, including adolescents and 
nulliparous women. All women should be counseled about 
the full range and effectiveness of contraceptive options for 
which they are medically eligible so that they can identify the 
optimal method (Figure 1).
In choosing a method of contraception, the risk for human 
immunodeficiency virus (HIV) infection and other sexually 
transmitted diseases (STDs) also should be considered. 
Although hormonal contraceptives and IUDs are highly 
effective at preventing pregnancy, they do not protect against 
STDs and HIV. Consistent and correct use of the male latex 
condom reduces the risk for HIV infection and other STDs, 
including chlamydial infection, gonorrhea, and trichomoniasis 
(32). On the basis of a limited number of clinical studies, when 
a male condom cannot be used properly to prevent infection, 
a female condom should be considered (32). All patients, 
regardless of contraceptive choice, should be counseled about 
the use of condoms and the risk for STDs, including HIV 
infection (32). Additional information about prevention 
and treatment of STDs is available from the CDC Sexually 
Transmitted Diseases Treatment Guidelines (32).
Maintaining Updated Guidance
As with any evidence-based guidance document, a key 
challenge is keeping the recommendations up to date as new 
scientific evidence becomes available. Working with WHO, 
CDC uses the continuous identification of research evidence 
(CIRE) system to ensure that WHO and CDC guidance is 
based on the best available evidence and that a mechanism 
is in place to update guidance when new evidence becomes 
available (33). CDC will continue to work with WHO to 
identify and assess all new relevant evidence and determine 
whether changes in the recommendations are warranted. In 
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most cases, U.S. SPR will follow any updates in the WHO 
guidance, which typically occurs every 3–4 years (or sooner 
if warranted by new data). In addition, CDC will review any 
interim WHO updates for their application in the United 
States. CDC also will identify and assess any new literature 
for the recommendations that are not included in the WHO 
guidance and will completely review U.S. SPR every 3–4 
years. Updates to the guidance can be found on the U.S. 
SPR website (http://www.cdc.gov/reproductivehealth/
UnintendedPregnancy/USSPR.htm).
How To Be Reasonably Certain that a 
Woman Is Not Pregnant
In most cases, a detailed history provides the most accurate 
assessment of pregnancy risk in a woman who is about to start 
using a contraceptive method. Several criteria for assessing 
pregnancy risk are listed in the recommendation that follows. 
These criteria are highly accurate (i.e., a negative predictive 
value of 99%–100%) in ruling out pregnancy among women 
who are not pregnant (34–37). Therefore, CDC recommends 
that health-care providers use these criteria to assess pregnancy 
TABLE 1. Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of 
contraception and the percentage continuing use at the end of the first year — United States
Method
% of women experiencing an unintended pregnancy 
within the first year of use
% of women continuing use at 1 year§Typical use* Perfect use†
No method¶ 85 85 —
Spermicides** 28 18 42
Fertility awareness–based methods†† 24 — 47
Standard days method — 5 —
Two day method — 4 —
Ovulation method — 3 —
Symptothermal method — 0.4 —
Withdrawal 22 4 46
Sponge
Parous women 24 20 36
Nulliparous women 12 9 —
Condom§§
Female 21 5 41
Male 18 2 43
Diaphragm*** 12 6 57
Combined pill and progestin-only pill 9 0.3 67
Evra patch 9 0.3 67
NuvaRing 9 0.3 67
Depo-Provera 6 0.2 56
Intrauterine devices
Paragard (copper containing) 0.8 0.6 78
Mirena (levenorgestrel releasing) 0.2 0.2 80
Implanon 0.05 0.05 84
Female sterilization 0.5 0.5 100
Male sterilization 0.15 0.10 100
Lactational amenorrhea method††† — — —
Source: Adapted from Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404. 
 * Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first 
year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides and the diaphragm 
are taken from the 1995 National Survey of Family Growth (NSFG) corrected for underreporting of abortion; estimates for fertility awareness-based methods, 
withdrawal, the male condom, the pill and Depo-Provera are taken from the 1995 and 2002 NSFG corrected for underreporting of abortion. 
 † Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who 
experience an accidental pregnancy during the first year if they do not stop use for any other reason. 
 § Among couples attempting to avoid pregnancy, the percentage who continues to use a method for 1 year.  
 ¶ The percentage becoming pregnant in the second and third columns are based on data from populations where contraception is not used and from women who 
cease using contraception to become pregnant. Among such populations, approximately 89% become pregnant within 1 year. This estimate was lowered slightly 
(to 85%) to represent the percentage who would become pregnant within 1 year among women not relying on reversible methods of contraception if they 
abandoned contraception altogether.
 ** Foams, creams, gels, vaginal suppositories, and vaginal film.
 †† The ovulation and two day methods are based on evaluation of cervical mucus. The standard days method avoids intercourse on cycle days 8–19. The symptothermal 
method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to 
determine the last fertile day.
 §§ Without spermicides.
 *** With spermicidal cream or jelly.
 ††† This is a highly effective, temporary method of contraception. However, to maintain in effective protection against pregnancy, another method of contraception must 
be used as soon as menstruation resumes, the frequency of duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches age 6 months.
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status in a woman who is about to start using contraceptives 
(Box 1). If a woman meets one of these criteria (and therefore 
the health-care provider can be reasonably certain that she is 
not pregnant), a urine pregnancy test might be considered 
in addition to these criteria (based on clinical judgment), 
bearing in mind the limitations of the accuracy of pregnancy 
testing. If a woman does not meet any of these criteria, then 
the health-care provider cannot be reasonably certain that she 
is not pregnant, even with a negative pregnancy test. Routine 
pregnancy testing for every woman is not necessary.
On the basis of clinical judgment, health-care providers 
might consider the addition of a urine pregnancy test; however, 
they should be aware of the limitations, including accuracy 
of the test relative to the time of last sexual intercourse, 
recent delivery, or spontaneous or induced abortion. Routine 
pregnancy testing for every woman is not necessary. If a woman 
has had recent (i.e., within the last 5 days) unprotected sexual 
intercourse, consider offering emergency contraception (either 
a Cu-IUD or ECPs), if pregnancy is not desired.
Comments and Evidence Summary. The criteria for 
determining whether a woman is pregnant depend on the 
assurance that she has not ovulated within a certain amount of 
time after her last menses, spontaneous or induced abortion, or 
delivery. Among menstruating women, the timing of ovulation 
can vary widely. During an average 28-day cycle, ovulation 
generally occurs during days 9–20 (38). In addition, the 
FIGURE 1.  Effectiveness of family planning methods
Sources: Adapted from World Health Organization (WHO) Department of Reproductive Health and Research, Johns Hopkins Bloomberg School of Public Health/
Center for Communication Programs (CCP). Knowledge for health project. Family planning: a global handbook for providers (2011 update). Baltimore, MD; Geneva, 
Switzerland: CCP and WHO; 2011; and Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404.
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likelihood of ovulation is low from days 1–7 of the menstrual 
cycle (39). After a spontaneous or an induced abortion, 
ovulation can occur within 2–3 weeks and has been found 
to occur as early as 8–13 days after the end of the pregnancy. 
Therefore, the likelihood of ovulation is low ≤7 days after an 
abortion (40–42). A recent systematic review reported that the 
mean day of first ovulation among postpartum nonlactating 
women occurred 45–94 days after delivery (43). In one study, 
the earliest ovulation was reported at 25 days after delivery. 
Among women who are within 6 months postpartum, are fully 
or nearly fully breastfeeding, and are amenorrheic, the risk for 
pregnancy is <2% (44).
Although pregnancy tests often are performed before 
initiating contraception, the accuracy of qualitative urine 
pregnancy tests varies depending on the timing of the test 
relative to missed menses, recent sexual intercourse, or recent 
pregnancy. The sensitivity of a pregnancy test is defined as 
the concentration of human chorionic gonadotropin (hCG) 
at which 95% of tests are positive. Most qualitative pregnancy 
tests approved by the U.S. Food and Drug Administration 
(FDA) report a sensitivity of 20–25 mIU/mL in urine (45–48) 
However, pregnancy detection rates can vary widely because of 
differences in test sensitivity and the timing of testing relative 
to missed menses (47,49). Some studies have shown that an 
additional 11 days past the day of expected menses are needed 
to detect 100% of pregnancies using qualitative tests (46). In 
addition, pregnancy tests cannot detect a pregnancy resulting 
from recent sexual intercourse. Qualitative tests also might have 
positive results for several weeks after termination of pregnancy 
because hCG can be present for several weeks after delivery or 
abortion (spontaneous or induced) (50–52).
For contraceptive methods other than IUDs, the benefits 
of starting to use a contraceptive method likely exceed any 
risk, even in situations in which the health-care provider is 
uncertain whether the woman is pregnant. Therefore, the 
health-care provider can consider having patients start using 
contraceptive methods other than IUDs at any time, with 
a follow-up pregnancy test in 2–4 weeks. The risks of not 
starting to use contraception should be weighed against the 
risks of initiating contraception use in a woman who might 
be already pregnant. Most studies have shown no increased 
risk for adverse outcomes, including congenital anomalies 
or neonatal or infant death, among infants exposed in utero 
to COCs (53–55). Studies also have shown no increased risk 
for neonatal or infant death or developmental abnormalities 
among infants exposed in utero to DMPA (54,56,57).
In contrast, for women who want to begin using an IUD 
(Cu-IUD or LNG-IUD), in situations in which the health-
care provider is uncertain whether the woman is pregnant, the 
woman should be provided with another contraceptive method 
to use until the health-care provider is reasonably certain that 
she is not pregnant and can insert the IUD. Pregnancies among 
women with IUDs are at higher risk for complications such as 
spontaneous abortion, septic abortion, preterm delivery, and 
chorioamnionitis (58).
A systematic review identified four analyses of data 
from three diagnostic accuracy studies that evaluated the 
performance of the criteria listed above through use of a 
pregnancy checklist compared with a urine pregnancy test 
conducted concurrently (12). The performance of the checklist 
to diagnose or exclude pregnancy varied, with sensitivity 
of 55%–100% and specificity of 39%–89%. The negative 
predictive value was consistent across studies at 99%–100%; 
the pregnancy checklist correctly ruled out women who were 
not pregnant. One of the studies assessed the added usefulness 
of signs and symptoms of pregnancy and found that these 
criteria did not substantially improve the performance of the 
pregnancy checklist, although the number of women with signs 
and symptoms was small (34) (Level of evidence: Diagnostic 
accuracy studies, fair, direct).
Intrauterine Contraception
Three IUDs are available in the United States, the Cu-IUD 
and two LNG-IUDs (containing a total of either 13.5 mg 
or 52 mg levonorgestrel). Fewer than 1 woman out of 100 
becomes pregnant in the first year of using IUDs (with typical 
use) (59). IUDs are long acting, are reversible, and can be 
BOX 1. How To Be Reasonably Certain that a Woman Is Not Pregnant
A health-care provider can be reasonably certain that a 
woman is not pregnant if she has no symptoms or signs 
of pregnancy and meets any one of the following criteria:
•	 is ≤7 days after the start of normal menses
•	 has not had sexual intercourse since the start of last 
normal menses
•	 has been correctly and consistently using a reliable 
method of contraception
•	 is ≤7 days after spontaneous or induced abortion
•	 is within 4 weeks postpartum 
•	 is fully or nearly fully breastfeeding (exclusively 
breastfeeding or the vast majority [≥85%] of feeds are 
breastfeeds),* amenorrheic, and <6 months 
postpartum
* Source: Labbok M, Perez A, Valdez V, et al. The Lactational Amenorrhea 
Method (LAM): a postpartum introductory family planning method with 
policy and program implications. Adv Contracept 1994;10:93–109.
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used by women of all ages, including adolescents, and both by 
parous and nulliparous women. IUDs do not protect against 
STDs; consistent and correct use of male latex condoms reduces 




certain that the woman is not pregnant (Box 1).
•	 The	Cu-IUD	also	can	be	inserted	within	5	days	of	the	first	
act of unprotected sexual intercourse as an emergency 
contraceptive. If the day of ovulation can be estimated, the 
Cu-IUD also can be inserted >5 days after sexual intercourse 
as long as insertion does not occur >5 days after ovulation.
Need for Back-Up Contraception




•	Timing: The Cu-IUD can be inserted at any time if it is 
reasonably certain that the woman is not pregnant (Box 1).
•	Need for back-up contraception: No additional contraceptive 
protection is needed.
Postpartum (Including After Cesarean Section)
•	 Timing: The Cu-IUD can be inserted at any time postpartum, 
including immediately postpartum (U.S. MEC 1 or 2) (Box 2), 
if it is reasonably certain that the woman is not pregnant 
(Box 1). The Cu-IUD should not be inserted in a woman with 
puerperal sepsis (U.S. MEC 4).
•	Need for back-up contraception: No additional 
contraceptive protection is needed.
Postabortion (Spontaneous or Induced)
•	Timing: The Cu-IUD can be inserted within the first 
7 days, including immediately postabortion (U.S. MEC 1 
for first trimester abortion and U.S. MEC 2 for second 
trimester abortion). The Cu-IUD should not be inserted 
immediately after septic abortion (U.S. MEC 4).
•	Need for back-up contraception: No additional 
contraceptive protection is needed.
Switching from Another Contraceptive Method
•	Timing: The Cu-IUD can be inserted immediately if it is 
reasonably certain that the woman is not pregnant (Box 1). 
Waiting for her next menstrual period is unnecessary.
•	Need for back-up contraception: No additional 
contraceptive protection is needed.
Comments and Evidence Summary. In situations in which 
the health-care provider is not reasonably certain that the 
woman is not pregnant, the woman should be provided with 
another contraceptive method to use until the health-care 
provider can be reasonably certain that she is not pregnant 
and can insert the Cu-IUD.
A systematic review identified eight studies that suggested that 
timing of Cu-IUD insertion in relation to the menstrual cycle in 
nonpostpartum women had little effect on long-term outcomes 
(rates of continuation, removal, expulsion, or pregnancy) or on 
short-term outcomes (pain at insertion, bleeding at insertion, or 
immediate expulsion) (13) (Level of evidence: II-2, fair, direct).
Initiation of LNG-IUDs
Timing of LNG-IUD Insertion
•	 The	LNG-IUD	can	be	inserted	at	any	time	if	it	is	reasonably	
certain that the woman is not pregnant (Box 1).
Need for Back-Up Contraception
•	 If	the	LNG-IUD	is	inserted	within	the	first	7	days	since	
menstrual bleeding started, no additional contraceptive 
protection is needed.
•	 If	the	LNG-IUD	is	inserted	>7	days	since	menstrual	bleeding	
started, the woman needs to abstain from sexual intercourse 
or use additional contraceptive protection for the next 7 days.
BOX 2. Categories of medical eligibility criteria for contraceptive use
U.S. MEC 1 = A condition for which there is no restriction 
for the use of the contraceptive method.
U.S. MEC 2 = A condition for which the advantages of 
using the method generally outweigh the theoretical or 
proven risks.
U.S. MEC 3 = A condition for which the theoretical or 
proven risks usually outweigh the advantages of using the 
method.
U.S. MEC 4 = A condition that represents an unacceptable 
health risk if the contraceptive method is used.
Abbreviations: U.S. MEC = U.S. Medical Eligibility Criteria for Contraceptive 
Use, 2010.
Source: CDC. U.S. medical eligibility criteria for contraceptive use. 
MMWR 2010;59(No. RR-4).
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Special Considerations
Amenorrhea (Not Postpartum)
•	Timing: The LNG-IUD can be inserted at any time if it is 
reasonably certain that the woman is not pregnant (Box 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
Postpartum (Including After Cesarean Section)
• Timing: The LNG-IUD can be inserted at any time, 
including immediately postpartum (U.S. MEC 1 or 2) if 
it is reasonably certain that the woman is not pregnant 
(Box 1). The LNG-IUD should not be inserted in a 
woman with puerperal sepsis (U.S. MEC 4).
•	Need for back-up contraception: If the woman is 
<6 months postpartum, amenorrheic, and fully or nearly 
fully breastfeeding (exclusively breastfeeding or the vast 
majority [≥85%] of feeds are breastfeeds) (60), no 
additional contraceptive protection is needed. Otherwise, 
a woman who is ≥21 days postpartum and has not 
experienced return of her menstrual cycle needs to abstain 
from sexual intercourse or use additional contraceptive 
protection for the next 7 days. If her menstrual cycles have 
returned and it has been >7 days since menstrual bleeding 
began, she needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 7 days.
Postabortion (Spontaneous or Induced)
•	Timing: The LNG-IUD can be inserted within the first 
7 days, including immediately postabortion (U.S. MEC 1 
for first-trimester abortion and U.S. MEC 2 for second-
trimester abortion). The LNG-IUD should not be inserted 
immediately after a septic abortion (U.S. MEC 4).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days unless the 
IUD is placed at the time of a surgical abortion.
Switching from Another Contraceptive Method
•	Timing: The LNG-IUD can be inserted immediately if it 
is reasonably certain that the woman is not pregnant (Box 1). 
Waiting for her next menstrual period is unnecessary.
•	Need for back-up contraception: If it has been >7 days 
since menstrual bleeding began, the woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
•	 Switching from a Cu-IUD: If the woman has had sexual 
intercourse since the start of her current menstrual cycle 
and it has been >5 days since menstrual bleeding started, 
theoretically, residual sperm might be in the genital tract, 
which could lead to fertilization if ovulation occurs. A 
health-care provider can consider providing ECPs at the 
time of LNG-IUD insertion.
Comments and Evidence Summary. In situations in which 
the health-care provider is uncertain whether the woman might 
be pregnant, the woman should be provided with another 
contraceptive method to use until the health-care provider 
can be reasonably certain that she is not pregnant and can 
insert the LNG-IUD. If a woman needs to use additional 
contraceptive protection when switching to an LNG-IUD 
from another contraceptive method, consider continuing her 
previous method for 7 days after LNG-IUD insertion. No 
direct evidence was found regarding the effects of inserting 
LNG-IUDs on different days of the cycle on short- or long-
term outcomes (13).
Examinations and Tests Needed Before 
Initiation of a Cu-IUD or an LNG-IUD
Among healthy women, few examinations or tests are needed 
before initiation of an IUD (Table 2). Bimanual examination 
and cervical inspection are necessary before IUD insertion. A 
baseline weight and BMI measurement might be useful for 
monitoring IUD users over time. If a woman has not been 
screened for STDs according to STD screening guidelines, 
screening can be performed at the time of insertion.  Women 
with known medical problems or other special conditions 
might need additional examinations or tests before being 
determined to be appropriate candidates for a particular 
method of contraception. U.S. MEC might be useful in such 
circumstances (5).
Comments and Evidence Summary. Weight (BMI): 
Obese women can use IUDs (U.S. MEC 1) (5); therefore, 
screening for obesity is not necessary for the safe initiation 
of IUDs. However, measuring weight and calculating BMI 
(weight [kg] / height [m]2) at baseline might be helpful for 
monitoring any changes and counseling women who might 
be concerned about weight change perceived to be associated 
with their contraceptive method.
Bimanual examination and cervical inspection: Bimanual 
examination and cervical inspection are necessary before IUD 
insertion to assess uterine size and position and to detect any 
cervical or uterine abnormalities that might indicate infection 
or otherwise prevent IUD insertion (61,62).
STDs: Women should be routinely screened for chlamydial 
infection and gonorrhea according to national screening 
guidelines. The CDC Sexually Transmitted Diseases Treatment 
Guidelines provide information on screening eligibility, timing, 
and frequency of screening and on screening for persons 
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with risk factors (32). If STD screening guidelines have been 
followed, most women do not need additional STD screening 
at the time of IUD insertion. If a woman has not been screened 
according to guidelines, screening can be performed at the time 
of IUD insertion and insertion should not be delayed. Women 
with purulent cervicitis or current chlamydial infection or 
gonorrhea should not undergo IUD insertion (U.S. MEC 4). 
Women who have a very high individual likelihood of STD 
exposure (e.g., those with a currently infected partner) generally 
should not undergo IUD insertion (U.S. MEC 3) (5). For these 
women, IUD insertion should be delayed until appropriate 
testing and treatment occur.  A systematic review did not 
identify any evidence regarding women who were screened 
versus not screened for STDs before IUD insertion (14). 
Although women with STDs at the time of IUD insertion 
have a higher risk for PID, the overall rate of PID among all 
IUD users is low (63,64).
Hemoglobin: Women with iron-deficiency anemia can use 
the LNG-IUD (U.S. MEC 1) (5); therefore, screening for 
anemia is not necessary for safe initiation of the LNG-IUD. 
Women with iron-deficiency anemia generally can use the 
Cu-IUD (U.S. MEC 2). Measurement of hemoglobin before 
initiation of Cu-IUDs is not necessary because of the minimal 
change in hemoglobin among women with and without anemia 
using Cu-IUDs. A systematic review identified four studies that 
provided direct evidence for changes in hemoglobin among 
women with anemia who received Cu-IUDs (30). Evidence 
from one randomized trial (65) and one prospective cohort 
study (66) showed no significant changes in hemoglobin 
among Cu-IUD users with anemia, whereas two prospective 
cohort studies (67,68) showed a statistically significant decrease 
in hemoglobin levels during 12 months of follow-up; however, 
the magnitude of the decrease was small and most likely not 
clinically significant. The systematic review also identified 21 
studies that provided indirect evidence by examining changes 
in hemoglobin among healthy women receiving Cu-IUDs 
(69–89), which generally showed no clinically significant 
changes in hemoglobin levels with up to 5 years of follow-up 
(Level of evidence: I to II-2, fair, direct).
Liver enzymes: Women with liver disease can use the 
Cu-IUD (U.S. MEC 1) (5); therefore, screening for liver 
disease is not necessary for the safe initiation of the Cu-IUD. 
Although women with certain liver diseases generally should 
not use the LNG-IUD (U.S. MEC 3) (5), screening for liver 
disease before initiation of the LNG-IUD is not necessary 
because of the low prevalence of these conditions and the 
high likelihood that women with liver disease already would 
have had the condition diagnosed. A systematic review did 
not identify any evidence regarding outcomes among women 
who were screened versus not screened with liver enzyme tests 
before initiation of hormonal contraceptive use (14). The 
prevalence of liver disorders among women of reproductive 
age is low. In 2008, among adults aged 18–44 years, the 
percentage with liver disease (not further specified) was 1.0% 
(90). In 2009, the incidence of acute hepatitis A, B, or C 
among women was <1 per 100,000 population (91). During 
1998–2007, the incidence of liver carcinoma among women 
was approximately 3 per 100,000 population (92). Because 
estrogen and progestins are metabolized in the liver, the use 
of hormonal contraceptives among women with liver disease 









Blood pressure C C
Weight (BMI) (weight [kg]/
height [m]2)
—† —†
Clinical breast examination C C






Liver enzymes C C
Hemoglobin C C




STD screening with 
laboratory tests
—§ —§
HIV screening with laboratory 
tests
C C
Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; 
IUD = intrauterine device; STD = sexually transmitted disease; U.S. MEC = U.S. 
Medical Eligibility Criteria for Contraceptive Use, 2010.
* Class A: essential and mandatory in all circumstances for safe and effective 
use of the contraceptive method. Class B: contributes substantially to safe 
and effective use, but implementation may be considered within the public 
health and/or service context; the risk of not performing an examination or 
test should be balanced against the benefits of making the contraceptive 
method available. Class C: does not contribute substantially to safe and 
effective use of the contraceptive method.
† Weight (BMI) measurement is not needed to determine medical eligibility for any 
methods of contraception because all methods can be used (U.S. MEC 1) or 
generally can be used (U.S. MEC 2) among obese women (Box 2). However, 
measuring weight and calculating BMI at baseline might be helpful for monitoring 
any changes and counseling women who might be concerned about weight 
change perceived to be associated with their contraceptive method.
§ Most women do not require additional STD screening at the time of IUD 
insertion if they have already been screened according to CDC’s STD Treatment 
Guidelines (available at http://www.cdc.gov/std/treatment). If a woman has 
not been screened according to guidelines, screening can be performed at 
the time of IUD insertion, and insertion should not be delayed. Women with 
purulent cervicitis or current chlamydial infection or gonorrhea should not 
undergo IUD insertion (U.S. MEC 4). Women who have a very high individual 
likelihood of STD exposure (e.g., those with a currently infected partner) 
generally should not undergo IUD insertion (U.S. MEC 3). For these women, 
IUD insertion should be delayed until appropriate testing and treatment occur.
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might, theoretically, be a concern. The use of hormonal 
contraceptives, specifically COCs and POPs, does not affect 
disease progression or severity in women with hepatitis, 
cirrhosis, or benign focal nodular hyperplasia (93,94), although 
evidence is limited, and no evidence exists for the LNG-IUD. 
Clinical breast examination: Women with breast disease 
can use the Cu-IUD (U.S. MEC 1) (5); therefore, screening 
for breast disease is not necessary for the safe initiation of 
the Cu-IUD. Although women with current breast cancer 
should not use the LNG-IUD (U.S. MEC 4) (5), screening 
asymptomatic women with a clinical breast examination 
before inserting an IUD is not necessary because of the low 
prevalence of breast cancer among women of reproductive 
age. A systematic review did not identify any evidence 
regarding outcomes among women who were screened versus 
not screened with a breast examination before initiation of 
hormonal contraceptives (15). The incidence of breast cancer 
among women of reproductive age in the United States is low. 
In 2009, the incidence of breast cancer among women aged 
20–49 years was approximately 72 per 100,000 women (95).
Cervical cytology: Although women with cervical cancer 
should not undergo IUD insertion (U.S. MEC 4) (5), 
screening asymptomatic women with cervical cytology before 
IUD insertion is not necessary because of the high rates of 
cervical screening, low incidence of cervical cancer in the 
United States, and high likelihood that a woman with cervical 
cancer already would have had the condition diagnosed. A 
systematic review did not identify any evidence regarding 
outcomes among women who were screened versus not 
screened with cervical cytology before initiation of IUDs (14). 
Cervical cancer is rare in the United States, with an incidence 
rate of 8.1 per 100,000 women per year during 2004–2008 
(95). The incidence and mortality rates from cervical cancer 
have declined dramatically in the United States, largely because 
of cervical cytology screening (96). Overall screening rates for 
cervical cancer in the United States are high; among women 
aged 22–30 years, approximately 87% reported having cervical 
cytology screening within the last 3 years (97).
HIV screening: Although women with acquired 
immunodeficiency syndrome (AIDS) who are not clinically 
well should generally not undergo IUD insertion (U.S. MEC 3) 
(5), HIV screening is not necessary before IUD insertion 
because of the high likelihood that a woman in the United 
States with such an advanced stage of disease already would 
have had the condition diagnosed. A systematic review did 
not identify any evidence regarding outcomes among women 
who were screened versus not screened for HIV infection 
before IUD insertion (14). Limited evidence suggests that 
IUDs are not associated with disease progression, increased 
infection, or other adverse health effects among women with 
HIV infection (98).
Other screening: Women with hypertension, diabetes, 
hyperlipidemia, or thrombogenic mutations can use 
(U.S. MEC 1) or generally can use (U.S. MEC 2) IUDs (5). 
Therefore, screening for these conditions is not necessary for 
the safe initiation of IUDs.
Provision of Prophylactic Antibiotics at the 
Time of IUD Insertion
•	 Prophylactic	antibiotics	are	generally	not	recommended	
for Cu-IUD or LNG-IUD insertion.
Comments and Evidence Summary. Theoretically, 
IUD insertion could induce bacterial spread and lead to 
complications such as PID or infective endocarditis. A 
metaanalysis was conducted of randomized controlled 
trials examining antibiotic prophylaxis versus placebo or 
no treatment for IUD insertion (99). Use of prophylaxis 
reduced the frequency of unscheduled return visits but did not 
significantly reduce the incidence of PID or premature IUD 
discontinuation. Although the risk for PID was higher within 
the first 20 days after insertion, the incidence of PID was low 
among all women who had IUDs inserted (63). In addition, 
the American Heart Association recommends that the use of 
prophylactic antibiotics solely to prevent infective endocarditis 
is not needed for genitourinary procedures (100). Studies have 
not demonstrated a conclusive link between genitourinary 
procedures and infective endocarditis or a preventive benefit 
of prophylactic antibiotics during such procedures (100).
Routine Follow-Up After IUD Insertion
These recommendations address when routine follow-up is 
needed for safe and effective continued use of contraception 
for healthy women. The recommendations refer to general 
situations and might vary for different users and different 
situations. Specific populations that might benefit from more 
frequent follow-up visits include adolescents, persons with 
certain medical conditions or characteristics, and persons with 
multiple medical conditions.
•	 Advise	a	woman	to	return	at	any	time	to	discuss	side	effects	or	
other problems, if she wants to change the method being used, 
and when it is time to remove or replace the contraceptive 
method. No routine follow-up visit is required.
•	 At	other	routine	visits,	health-care	providers	who	see	IUD	
users should do the following:
 – Assess the woman’s satisfaction with her contraceptive 
method and whether she has any concerns about 
method use.
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 – Assess any changes in health status, including 
medications, that would change the appropriateness of 
the IUD for safe and effective continued use on the 
basis of U.S. MEC (e.g., category 3 and 4 conditions 
and characteristics).
 – Consider performing an examination to check for the 
presence of the IUD strings.
 – Consider assessing weight changes and counseling women 
who are concerned about weight changes perceived to be 
associated with their contraceptive method. 
Comments and Evidence Summary. Evidence from a 
systematic review about the effect of a specific follow-up visit 
schedule on IUD continuation is very limited and of poor 
quality. The evidence did not suggest that greater frequency of 
visits or earlier timing of the first follow-up visit after insertion 
improves continuation of use (16) (Level of evidence: II-2, 
poor, direct). Evidence from four studies from a systematic 
review on the incidence of PID among IUD initiators, or 
IUD removal as a result of PID, suggested that the incidence 
of PID did not differ between women using Cu-IUDs and 
those using DMPA, COCs, or LNG-IUDs (17) (Level of 
evidence: I to II-2, good, indirect). Evidence on the timing of 
PID after IUD insertion is mixed. Although the rate of PID 
was generally low, the largest study suggested that the rate of 
PID was significantly higher in the first 20 days after insertion 
(63) (Level of evidence: I to II-3, good to poor, indirect).
Bleeding Irregularities with Cu-IUD Use
•	 Before	Cu-IUD	 insertion,	 provide	 counseling	 about	
potential changes in bleeding patterns during Cu-IUD 
use. Unscheduled spotting or light bleeding, as well as 
heavy or prolonged bleeding, is common during the first 
3–6 months of Cu-IUD use,  is generally not harmful, 
and decreases with continued Cu-IUD use.
•	 If	clinically	indicated,	consider	an	underlying	gynecological	
problem, such as Cu-IUD displacement, an STD, 
pregnancy, or new pathologic uterine conditions (e.g., 
polyps or fibroids), especially in women who have already 
been using the Cu-IUD for a few months or longer and 
who have developed a new onset of heavy or prolonged 
bleeding. If an underlying gynecological problem is found, 
treat the condition or refer for care.
•	 If	an	underlying	gynecological	problem	is	not	found	and	
the woman requests treatment, the following treatment 
option can be considered during days of bleeding:
 – Nonsteroidal antiinflammatory drugs (NSAIDs) for 
short-term treatment (5–7 days)
•	 If	bleeding	persists	and	the	woman	finds	it	unacceptable,	
counsel her on alternative contraceptive methods, and 
offer another method if it is desired.
Comments and Evidence Summary. During contraceptive 
counseling and before insertion of the Cu-IUD, information 
about common side effects such as unscheduled spotting or 
light bleeding or heavy or prolonged menstrual bleeding, 
especially during the first 3–6 months of use, should be 
discussed (70). These bleeding irregularities are generally 
not harmful. Enhanced counseling about expected bleeding 
patterns and reassurance that bleeding irregularities are 
generally not harmful has been shown to reduce method 
discontinuation in clinical trials with other contraceptives (i.e., 
DMPA) (101,102).
Evidence is limited on specific drugs, doses, and durations 
of use for effective treatments for bleeding irregularities with 
Cu-IUD use; therefore, although this document includes 
general recommendations for treatments to consider, evidence 
for specific regimens is lacking.
A systematic review identified 11 articles that examined 
various therapeutic treatments for heavy menstrual bleeding, 
prolonged menstrual bleeding, or both among women using 
Cu-IUDs (18). Nine studies examined the use of various oral 
NSAIDs for the treatment of heavy or prolonged menstrual 
bleeding among Cu-IUD users and compared them to either 
a placebo or a baseline cycle. Three of these trials examined 
the use of indomethacin (103–105), another three examined 
mefenamic acid (106–108), and another three examined 
flufenamic acid (103,104,109). Other NSAIDs used in the 
reported trials included alclofenac (103,104), suprofen (110), 
and diclofenac sodium (111). All but one NSAID study (107) 
demonstrated statistically significant or notable reductions in 
mean total menstrual blood loss with NSAID use. One study 
among 19 Cu-IUD users with heavy bleeding suggested that 
treatment with oral tranexamic acid can significantly reduce 
mean blood loss during treatment compared with placebo 
(111). Data regarding the overall safety of tranexamic acid 
are limited; an FDA warning states that tranexamic acid 
is contraindicated in women with active thromboembolic 
disease or with a history or intrinsic risk for thrombosis 
or thromboembolism (112,113). Treatment with aspirin 
demonstrated no statistically significant change in mean blood 
loss among women whose pretreatment menstrual blood loss 
was >80 mL or 60–80 mL; treatment resulted in a significant 
increase among women whose pretreatment menstrual 
blood loss was <60 mL (114). One study examined the use 
of a synthetic form of vasopressin, intranasal desmopressin 
(300 µg/day), for the first 5 days of menses for three treatment 
cycles and found a significant reduction in mean blood loss 
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compared with baseline (106) (Level of evidence: I to II-3, 
poor to fair, direct). Only one small study examined treatment 
of spotting with three separate NSAIDs and did not observe 
improvements in spotting in any of the groups (103) (Level 
of evidence: I, poor, direct).
Bleeding Irregularities (Including 
Amenorrhea) with LNG-IUD Use
•	 Before	LNG-IUD	 insertion,	 provide	 counseling	 about	
potential changes in bleeding patterns during LNG-IUD 
use. Unscheduled spotting or light bleeding is expected 
during the first 3–6 months of LNG-IUD use, is generally 
not harmful, and decreases with continued LNG-IUD 
use. Over time, bleeding generally decreases with LNG-
IUD use, and many women experience only light 
menstrual bleeding or amenorrhea. Heavy or prolonged 
bleeding, either unscheduled or menstrual, is uncommon 
during LNG-IUD use.
Irregular Bleeding (Spotting, Light Bleeding, or 
Heavy or Prolonged Bleeding)
•	 If	clinically	indicated,	consider	an	underlying	gynecological	
problem, such as LNG-IUD displacement, an STD, 
pregnancy, or new pathologic uterine conditions (e.g., 
polyps or fibroids). If an underlying gynecological problem 
is found, treat the condition or refer for care.
•	 If	bleeding	persists	and	the	woman	finds	it	unacceptable,	
counsel her on alternative contraceptive methods, and 
offer another method if it is desired.
Amenorrhea
•	 Amenorrhea	 does	 not	 require	 any	medical	 treatment.	
Provide reassurance.
 – If a woman’s regular bleeding pattern changes abruptly 
to amenorrhea, consider ruling out pregnancy if 
clinically indicated.
•	 If	amenorrhea	persists	and	the	woman	finds	it	unacceptable,	
counsel her on alternative contraceptive methods, and 
offer another method if it is desired
Comments and Evidence Summary. During contraceptive 
counseling and before insertion of the LNG-IUD, information 
about common side effects such as unscheduled spotting 
or light bleeding, especially during the first 3–6 months of 
use, should be discussed. Approximately half of LNG-IUD 
users are likely to experience amenorrhea or oligomenorrhea 
by 2 years of use (115). These bleeding irregularities are 
generally not harmful. Enhanced counseling about expected 
bleeding patterns and reassurance that bleeding irregularities 
are generally not harmful has been shown to reduce method 
discontinuation in clinical trials with other hormonal 
contraceptives (i.e., DMPA) (101,102). No direct evidence 
was found regarding therapeutic treatments for bleeding 
irregularities during LNG-IUD use.
Management of the IUD when a Cu-IUD or 
an LNG-IUD User Is Found To Have PID
•	 Treat	the	PID	according	to	the	CDC	Sexually Transmitted 
Diseases Treatment Guidelines (32).
•	 Provide	comprehensive	management	for	STDs,	including	
counseling about condom use.
•	 The	IUD	does	not	need	to	be	removed	immediately	if	the	
woman needs ongoing contraception.
•	 Reassess	 the	 woman	 in	 48–72	 hours.	 If	 no	 clinical	
improvement occurs, continue antibiotics and consider 
removal of the IUD.
•	 If	 the	woman	wants	 to	discontinue	use,	 remove	 the	 IUD	
sometime after antibiotics have been started to avoid the potential 
risk for bacterial spread resulting from the removal procedure.
•	 If	 the	 IUD	 is	 removed,	 consider	ECPs	 if	 appropriate.	
Counsel the woman on alternative contraceptive methods, 
and offer another method if it is desired.
•	 A	summary	of	IUD	management	in	women	with	PID	is	
provided (Appendix F).
Comments and Evidence Summary. Treatment outcomes 
do not generally differ between women with PID who retain 
the IUD and those who have the IUD removed; however, 
appropriate antibiotic treatment and close clinical follow-up 
are necessary.
A systematic review identified four studies that included 
women using copper or nonhormonal IUDs who developed 
PID and compared outcomes between women who had the 
IUD removed or did not (19). One randomized trial showed 
that women with IUDs removed had longer hospitalizations 
than those who did not, although no differences in PID 
recurrences or subsequent pregnancies were observed (116). 
Another randomized trial showed no differences in laboratory 
findings among women who removed the IUD compared 
with those who did not (117). One prospective cohort study 
showed no differences in clinical or laboratory findings during 
hospitalization; however, the IUD removal group had longer 
hospitalizations (118). One randomized trial showed that 
the rate of recovery for most clinical signs and symptoms 
was higher among women who had the IUD removed than 
among women who did not (119). No evidence was found 
regarding women using LNG-IUDs (Level of evidence: I to 
II-2, fair, direct).
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Management of the IUD when a Cu-IUD or 
an LNG-IUD User Is Found To Be Pregnant
•	 Evaluate	for	possible	ectopic	pregnancy.
•	 Advise	 the	woman	 that	 she	 has	 an	 increased	 risk	 for	
spontaneous abortion (including septic abortion that 
might be life threatening) and of preterm delivery if the 
IUD is left in place. The removal of the IUD reduces these 
risks but might not decrease the risk to the baseline level 
of a pregnancy without an IUD.
 – If she does not want to continue the pregnancy, counsel 
her about options.
 – If she wants continue the pregnancy, advise her to seek 
care promptly if she has heavy bleeding, cramping, pain, 
abnormal vaginal discharge, or fever.
IUD Strings Are Visible or Can Be Retrieved Safely 
from the Cervical Canal
•	 Advise	the	woman	that	the	IUD	should	be	removed	as	
soon as possible.
 – If the IUD is to be removed, remove it by pulling on 
the strings gently.
 – Advise the woman that she should return promptly if 
she has heavy bleeding, cramping, pain, abnormal 
vaginal discharge, or fever.
•	 If	she	chooses	to	keep	the	IUD,	advise	her	to	seek	care	
promptly if she has heavy bleeding, cramping, pain, 
abnormal vaginal discharge, or fever.
IUD Strings Are Not Visible and Cannot Be  
Retrieved Safely
•	 If	 ultrasonography	 is	 available,	 consider	 performing	or	
referring for ultrasound examination to determine the 
location of the IUD. If the IUD cannot be located, it might 
have been expelled or have perforated the uterine wall.
•	 If	ultrasonography	is	not	possible	or	the	IUD	is	determined	
by ultrasound to be inside the uterus, advise the woman 
to seek care promptly if she has heavy bleeding, cramping, 
pain, abnormal vaginal discharge, or fever.
Comments and Evidence Summary. Removing the IUD 
improves the pregnancy outcome if the IUD strings are visible 
or the device can be retrieved safely from the cervical canal. 
Risks for spontaneous abortion, preterm delivery, and infection 
are substantial if the IUD is left in place.
Theoretically, the fetus might be affected by hormonal 
exposure from an LNG-IUD; however, whether this exposure 
increases the risk for fetal abnormalities is unknown.
A systematic review identified nine studies suggesting that 
women who did not remove their IUDs during pregnancy 
were at greater risk for adverse pregnancy outcomes (including 
spontaneous abortion, septic abortion, preterm delivery, and 
chorioamnionitis) compared with women who had their IUDs 
removed or who did not have an IUD (58). Cu-IUD removal 
decreased risks but not to the baseline risk for pregnancies 
without an IUD. One case series examined LNG-IUDs. 
When they were not removed, eight in 10 pregnancies ended 
in spontaneous abortions (Level of evidence: II-2, fair, direct).
Implants
The etonogestrel implant, a single rod with 68 mg of 
etonogestrel, is available in the United States. Fewer than 1 
woman out of 100 become pregnant in the first year of use of 
the etonogestrel implant with typical use (59). The implant is 
long acting, is reversible, and can be used by women of all ages, 
including adolescents. The implant does not protect against 
STDs; consistent and correct use of male latex condoms reduces 




certain that the woman is not pregnant (Box 1).
Need for Back-Up Contraception
•	 If	 the	 implant	 is	 inserted	within	 the	 first	 5	 days	 since	
menstrual bleeding started, no additional contraceptive 
protection is needed.
•	 If	the	implant	is	inserted	>5	days	since	menstrual	bleeding	
started, the woman needs to abstain from sexual intercourse 
or use additional contraceptive protection for the next 7 days.
Special Considerations
Amenorrhea (Not Postpartum)
•	Timing: The implant can be inserted at any time if it is 
reasonably certain that the woman is not pregnant (Box 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
Postpartum (Breastfeeding)
•	Timing: The implant can be inserted at any time (U.S. 
MEC 2 if <1 month postpartum and U.S. MEC 1 if ≥1 
month postpartum) if it is reasonably certain that the 
woman is not pregnant (Box 1).
•	 Need for back-up contraception: If the woman is <6 months 
postpartum, amenorrheic, and fully or nearly fully breastfeeding 
(exclusively breastfeeding or the vast majority [≥85%] of feeds 
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are breastfeeds) (60), no additional contraceptive protection is 
needed. Otherwise, a woman who is ≥21 days postpartum and 
has not experienced return of her menstrual cycle needs to 
abstain from sexual intercourse or use additional contraceptive 
protection for the next 7 days. If her menstrual cycles have 
returned and it has been >5 days since menstrual bleeding 
started, she needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 7 days.
Postpartum (Not Breastfeeding)
•	Timing: The implant can be inserted at any time, including 
immediately postpartum (U.S. MEC 1) if it is reasonably 
certain that the woman is not pregnant (Box 1).
•	Need for back-up contraception: A woman who is 
≥21 days postpartum and has not experienced return of 
her menstrual cycle needs to abstain from sexual 
intercourse or use additional contraceptive protection for 
the next 7 days. If her menstrual cycles have returned and 
it has been >5 days since menstrual bleeding started, she 
needs to abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
Postabortion (Spontaneous or Induced)
•	Timing: The implant can be inserted within the first 7 days, 
including immediately after the abortion (U.S. MEC 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days unless the 
implant is placed at the time of a surgical abortion.
Switching from Another Contraceptive Method
•	Timing: The implant can be inserted immediately if it is 
reasonably certain that the woman is not pregnant (Box 1). 
Waiting for her next menstrual period is unnecessary.
•	Need for back-up contraception: If it has been >5 days 
since menstrual bleeding started, the woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days after insertion.
•	 Switching from an IUD: If the woman has had sexual 
intercourse since the start of her current menstrual cycle and 
it has been >5 days since menstrual bleeding started, 
theoretically, residual sperm might be in the genital tract, 
which could lead to fertilization if ovulation occurs. A health-
care provider may consider any of the following options:
 – Advise the woman to retain the IUD for at least 7 days 
after the implant is inserted and return for IUD removal.
 – Advise the woman to abstain from sexual intercourse 
or use barrier contraception for 7 days before removing 
the IUD and switching to the new method.
 – Advise the woman to use ECPs at the time of IUD removal.
Comments and Evidence Summary. In situations in which 
the health-care provider is uncertain whether the woman might 
be pregnant, the benefits of starting the implant likely exceed 
any risk; therefore, starting the implant should be considered 
at any time, with a follow-up pregnancy test in 2–4 weeks.
If a woman needs to use additional contraceptive protection 
when switching to an implant from another contraceptive 
method, consider continuing her previous method for 7 days 
after implant insertion. No direct evidence was found regarding 
the effects of starting the etonogestrel implant at different 
times of the cycle.
Examinations and Tests Needed Before 
Implant Insertion
Among healthy women, no examinations or tests are needed 
before initiation of an implant, although a baseline weight and 
BMI measurement might be useful for monitoring implant 
users over time (Table 3). Women with known medical 
problems or other special conditions might need additional 
examinations or tests before being determined to be appropriate 
candidates for a particular method of contraception. U.S. MEC 
might be useful in such circumstances (5).
TABLE 3. Classification of examinations and tests needed before 
implant insertion
Examination or test Class*
Examination
Blood pressure C
Weight (BMI) (weight [kg]/height [m]2) —†
Clinical breast examination C







Cervical cytology (Papanicolaou smear) C
STD screening with laboratory tests C
HIV screening with laboratory tests C
Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; 
STD = sexually transmitted disease; U.S. MEC = U.S. Medical Eligibility Criteria for 
Contraceptive Use, 2010.
* Class A: essential and mandatory in all circumstances for safe and effective 
use of the contraceptive method. Class B: contributes substantially to safe and 
effective use, but implementation may be considered within the public health 
and/or service context; the risk of not performing an examination or test should 
be balanced against the benefits of making the contraceptive method 
available. Class C: does not contribute substantially to safe and effective use 
of the contraceptive method.
† Weight (BMI) measurement is not needed to determine medical eligibility for 
any methods of contraception because all methods can be used (U.S. MEC 1) or 
generally can be used (U.S. MEC 2) among obese women (Box 2). However, 
measuring weight and calculating BMI at baseline might be helpful for 
monitoring any changes and counseling women who might be concerned about 
weight change perceived to be associated with their contraceptive method. 
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Comments and Evidence Summary. Weight (BMI): Obese 
women can use implants (U.S. MEC 1) (5); therefore, screening 
for obesity is not necessary for the safe initiation of implants. 
However, measuring weight and calculating BMI at baseline 
might be helpful for monitoring any changes and counseling 
women who might be concerned about weight change perceived 
to be associated with their contraceptive method.
Bimanual examination and cervical inspection: A pelvic 
examination is not necessary before initiation of implants 
because it would not facilitate detection of conditions for which 
implant use would be unsafe. Women with current breast cancer 
should not use implants (U.S. MEC 4); women with certain 
liver diseases generally should not use implants (U.S. MEC 3) 
(5). However, none of these conditions are likely to be detected 
by pelvic examination (120). A systematic review identified 
two case-control studies that compared delayed and immediate 
pelvic examination before initiation of hormonal contraceptives, 
specifically oral contraceptives or DMPA (15). No differences in 
risk factors for cervical neoplasia, incidence of STDs, incidence 
of abnormal Papanicolaou smears, or incidence of abnormal 
wet mounts were observed. No evidence was found regarding 
implants (Level of evidence: II-2 fair, direct).
Liver enzymes: Although women with certain liver diseases 
generally should not use implants (U.S. MEC 3) (5), screening 
for liver disease before initiation of implants is not necessary 
because of the low prevalence of these conditions and the 
high likelihood that women with liver disease already would 
have had the condition diagnosed. A systematic review did 
not identify any evidence regarding outcomes among women 
who were screened versus not screened with liver enzyme 
tests before initiation of hormonal contraceptives (14). The 
prevalence of liver disorders among women of reproductive 
age is low. In 2008, the percentage of adults aged 18–44 
years with liver disease (not further specified) was 1.0% 
(90). In 2009, the incidence of acute hepatitis A, B, or C 
among women was <1 per 100,000 population (91). During 
1998–2007, the incidence of liver carcinoma among women 
was approximately 3 per 100,000 population (92). Because 
estrogen and progestins are metabolized in the liver, the use 
of hormonal contraceptives among women with liver disease 
might, theoretically, be a concern. The use of hormonal 
contraceptives, specifically COCs and POPs, does not affect 
disease progression or severity in women with hepatitis, 
cirrhosis, or benign focal nodular hyperplasia (93,94), although 
evidence is limited and no evidence exists for implants.
Clinical breast examination: Although women with 
current breast cancer should not use implants (U.S. MEC 4) 
(5), screening asymptomatic women with a clinical breast 
examination before initiating an implant is not necessary 
because of the low prevalence of breast cancer among women 
of reproductive age (15–49 years). A systematic review did not 
identify any evidence regarding outcomes among women who 
were screened versus not screened with a breast examination 
before initiation of hormonal contraceptives (15). The 
incidence of breast cancer among women of reproductive age 
in the United States is low. In 2009, the incidence of breast 
cancer among women aged 20–49 years was approximately 72 
per 100,000 women (95).
Other screening: Women with hypertension, diabetes, 
hyperlipidemia, anemia, thrombogenic mutations, cervical 
intraepithelial neoplasia, cervical cancer, STDs, or HIV infection 
can use (U.S. MEC 1) or generally can use (U.S. MEC 2) 
implants (5); therefore, screening for these conditions is not 
necessary for the safe initiation of implants.
Routine Follow-Up After Implant Insertion
These recommendations address when routine follow-up is 
needed for safe and effective continued use of contraception 
for healthy women. The recommendations refer to general 
situations and might vary for different users and different 
situations. Specific populations that might benefit from more 
frequent follow-up visits include adolescents, those with certain 
medical conditions or characteristics, and those with multiple 
medical conditions.
•	 Advise	a	woman	to	return	at	any	time	to	discuss	side	effects	
or other problems, if she wants to change the method being 
used, and when it is time to remove or replace the 
contraceptive method. No routine follow-up visit is required.
•	 At	other	routine	visits,	health-care	providers	seeing	implant	
users should do the following:
 – Assess the woman’s satisfaction with her contraceptive 
method and whether she has any concerns about 
method use.
 – Assess any changes in health status, including 
medications, that would change the appropriateness of 
the implant for safe and effective continued use based 
on U.S. MEC (e.g., category 3 and 4 conditions and 
characteristics).
 – Consider assessing weight changes and counseling women 
who are concerned about weight changes perceived to be 
associated with their contraceptive method.
Comments and Evidence Summary. A systematic review 
did not identify any evidence regarding whether a routine 
follow-up visit after initiating an implant improves correct or 
continued use (16).
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Bleeding Irregularities (Including 
Amenorrhea) During Implant Use
•	 Before	 implant	 insertion,	 provide	 counseling	 about	
potential changes in bleeding patterns during implant use. 
Unscheduled spotting or light bleeding is common with 
implant use, and some women experience amenorrhea. 
These bleeding changes are generally not harmful and 
might or might not decrease with continued implant use. 
Heavy or prolonged bleeding, unscheduled or menstrual, 
is uncommon during implant use.
Irregular Bleeding (Spotting, Light Bleeding, or 
Heavy or Prolonged Bleeding)
•	 If	clinically	indicated,	consider	an	underlying	gynecological	
problem, such as interactions with other medications, an 
STD, pregnancy, or new pathologic uterine conditions 
(e.g., polyps or fibroids). If an underlying gynecological 
problem is found, treat the condition or refer for care.
•	 If	an	underlying	gynecologic	problem	is	not	found	and	
the woman wants treatment, the following treatment 
options during days of bleeding can be considered:
 – NSAIDS for short-term treatment (5–7 days)
 – Hormonal treatment (if medically eligible) with low-
dose COCs or estrogen for short-term treatment 
(10–20 days)
•	 If	 irregular	 bleeding	 persists	 and	 the	woman	 finds	 it	
unacceptable, counsel her on alternative methods, and 
offer another method if it is desired.
Amenorrhea
•	 Amenorrhea	 does	 not	 require	 any	medical	 treatment.	
Provide reassurance.
 – If a woman’s regular bleeding pattern changes abruptly 
to amenorrhea, consider ruling out pregnancy if 
clinically indicated.
•	 If	amenorrhea	persists	and	the	woman	finds	it	unacceptable,	
counsel her on alternative contraceptive methods, and 
offer another method if it is desired.
Comments and Evidence Summary. During contraceptive 
counseling and before insertion of the implant, information 
about common side effects, such as unscheduled spotting or 
light bleeding and amenorrhea, especially during the first 
year of use should be discussed. A pooled analysis of data 
from 11 clinical trials indicate that a significant proportion of 
etonogestrel implant users had relatively little bleeding: 22% 
of women experienced amenorrhea and 34% experienced 
infrequent spotting, although 7% reported frequent bleeding 
and 18% reported prolonged bleeding (121). Unscheduled 
bleeding or amenorrhea is generally not harmful. Enhanced 
counseling about expected bleeding patterns and reassurance 
that bleeding irregularities are generally not harmful has been 
shown to reduce discontinuation in clinical trials with other 
hormonal contraceptives (i.e., DMPA) (101,102).
A systematic review and four newly published studies 
examined several medications for the treatment of bleeding 
irregularities with primarily LNG contraceptive implants 
(122–126). Two small studies found significant cessation of 
bleeding within 7 days of start of treatment among women 
taking oral celecoxib (200 mg) daily for 5 days or oral 
mefenamic acid (500 mg) 3 times daily for 5 days compared 
with placebo (124,125). Differences in bleeding cessation 
were not found among women with etonogestrel implants 
taking mifepristone but were found when women with the 
implants combined mifepristone with either ethinyl estradiol 
or doxycycline (126,127). Doxycycline alone or in combination 
with ethinyl estradiol did not improve bleeding cessation 
among etonogestrel implant users (126). Among LNG implant 
users, mifepristone reduced the number of bleeding or spotting 
days but only after 6 months of treatment (128). Evidence 
also suggests that estrogen (129–131), daily COCs (129), 
levonorgestrel pills (130), tamoxifen (132), or tranexamic 
acid (133) can reduce the number of bleeding or spotting 
days during treatment among levonorgestrel implant users. In 
one small study, vitamin E was found to significantly reduce 
the mean number of bleeding days after the first treatment 
cycle; however, another larger study reported no significant 
differences in length of bleeding and spotting episodes with 
vitamin E treatment (134,135). Use of aspirin did not result 
in a significant difference in median length of bleeding or 
bleeding and spotting episodes after treatment (134). One 
study among implant users reported a reduction in number of 
bleeding days after initiating ibuprofen; however, another trial 
did not demonstrate any significant differences in the number 
of spotting and bleeding episodes with ibuprofen compared 
with placebo (123,130).
Injectables
Progestin-only injectable contraceptives (DMPA, 150 mg 
intramuscularly or 104 mg subcutaneously) are available in 
the United States; the only difference between these two 
formulations is the route of administration. Approximately 6 
out of 100 women will become pregnant in the first year of use 
of DMPA with typical use (59). DMPA is reversible and can 
be used by women of all ages, including adolescents. DMPA 
does not protect against STDs; consistent and correct use of 
male latex condoms reduces the risk for STDs, including HIV.
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reasonably certain that the woman is not pregnant (Box 1).
Need for Back-Up Contraception
•	 If	DMPA	is	started	within	the	first	7	days	since	menstrual	
bleeding started, no additional contraceptive protection 
is needed.
•	 If	DMPA	is	started	>7	days	since	menstrual	bleeding	started,	
the woman needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 7 days.
Special Considerations
Amenorrhea (Not Postpartum)
•	Timing: The first DMPA injection can be given at any 
time if it is reasonably certain that the woman is not 
pregnant (Box 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
Postpartum (Breastfeeding)
•	Timing: The first DMPA injection can be given at any 
time, including immediately postpartum (U.S. MEC 2 if 
<1 month postpartum and U.S. MEC 1 if ≥1 month 
postpartum) if it is reasonably certain that the woman is 
not pregnant (Box 1).
•	Need for back-up contraception: If the woman is 
<6 months postpartum, amenorrheic, and fully or nearly 
fully breastfeeding (exclusively breastfeeding or the vast 
majority [≥85%] of feeds are breastfeeds) (60), no 
additional contraceptive protection is needed. Otherwise, 
a woman who is ≥21 days postpartum and has not 
experienced return of her menstrual cycle needs to abstain 
from sexual intercourse or use additional contraceptive 
protection for the next 7 days. If her menstrual cycles have 
returned and it has been >7 days since menstrual bleeding 
started, she needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 7 days.
Postpartum (Not Breastfeeding)
•	Timing: The first DMPA injection can be given at any 
time, including immediately postpartum (U.S. MEC 1) 
if it is reasonably certain that the woman is not pregnant 
(Box 1).
•	Need for back-up contraception: A woman who is 
≥21 days postpartum and has not experienced return of 
her menstrual cycle needs to abstain from sexual 
intercourse or use additional contraceptive protection for 
the next 7 days. If her menstrual cycles have returned and 
it has been >7 days since menstrual bleeding started, she 
needs to abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
Postabortion (Spontaneous or Induced)
•	Timing: The first DMPA injection can be given within 
the first 7 days, including immediately postabortion 
(U.S. MEC 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days unless the 
injection is given at the time of a surgical abortion.
Switching from Another Contraceptive Method
•	Timing: The first DMPA injection can be given 
immediately if it is reasonably certain that the woman is 
not pregnant (Box 1). Waiting for her next menstrual 
period is unnecessary.
•	Need for back-up contraception: If it has been >7 days 
since menstrual bleeding started, the woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
•	 Switching from an IUD: If the woman has had sexual 
intercourse since the start of her current menstrual cycle and 
it has been >5 days since menstrual bleeding started, 
theoretically, residual sperm might be in the genital tract, 
which could lead to fertilization if ovulation occurs. A health-
care provider may consider any of the following options:
 – Advise the women to retain the IUD for at least 7 days 
after the injection and return for IUD removal.
 – Advise the woman to abstain from sexual intercourse 
or use barrier contraception for 7 days before removing 
the IUD and switching to the new method.
 – Advise the woman to use ECPs at the time of IUD removal.
Comments and Evidence Summary. In situations in which 
the health-care provider is uncertain whether the woman might 
be pregnant, the benefits of starting DMPA likely exceed 
any risk; therefore, starting DMPA should be considered at 
any time, with a follow-up pregnancy test in 2–4 weeks. If a 
woman needs to use additional contraceptive protection when 
switching to DMPA from another contraceptive method, 
consider continuing her previous method for 7 days after 
DMPA injection.
A systematic review identified eight articles examining 
DMPA initiation on different days of the menstrual cycle (20). 
Evidence from two studies with small samples indicated that 
DMPA injections given up to day 7 of the menstrual cycle 
inhibited ovulation; when DMPA was administered after 
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day 7, ovulation occurred in some women. Cervical mucus 
was of poor quality (i.e., not favorable for sperm penetration) 
in 90% of women within 24 hours of the injection (Level 
of evidence: II-2, fair) (136–138). Studies found that use of 
another contraceptive method until DMPA could be initiated 
(bridging option) did not help women initiate DMPA and was 
associated with more unintended pregnancies than immediate 
receipt of DMPA (139–143) (Level of evidence: I to II-3, fair 
to poor, indirect).
Examinations and Tests Needed Before 
Initiation of an Injectable
Among healthy women, no examinations or tests are needed 
before initiation of DMPA, although a baseline weight and 
BMI measurement might be useful for monitoring DMPA users 
over time (Table 4). Women with known medical problems or 
other special conditions might need additional examinations 
or tests before being determined to be appropriate candidates 
for a particular method of contraception. U.S. MEC might 
be useful in such circumstances (5).
Comments and Evidence Summary. Weight (BMI): Obese 
women can use (U.S. MEC 1) or generally can use (U.S. MEC 2) 
DMPA (5); therefore, screening for obesity is not necessary for 
the safe initiation of DMPA. However, measuring weight and 
calculating BMI at baseline might be helpful for monitoring 
any changes and counseling women who might be concerned 
about weight change perceived to be associated with their 
contraceptive method. (See guidance on follow-up for DMPA 
users for evidence on weight gain with DMPA use.)
Bimanual examination and cervical inspection: Pelvic 
examination is not necessary before initiation of DMPA 
because it does not facilitate detection of conditions for 
which DMPA would be unsafe. Although women with 
current breast cancer should not use DMPA (U.S. MEC 4), 
and women with severe hypertension, heart disease, vascular 
disease, migraine headaches with aura, or certain liver diseases 
generally should not use DMPA (U.S. MEC 3) (5), none of 
these conditions are likely to be detected by pelvic examination 
(120). A systematic review identified two case-control studies 
that compared delayed versus immediate pelvic examination 
before initiation of hormonal contraceptives, specifically oral 
contraceptives or DMPA (15). No differences in risk factors for 
cervical neoplasia, incidence of STDs, incidence of abnormal 
Papanicolaou smears, or incidence of abnormal wet mounts 
were observed (Level of evidence: II-2, fair, direct).
Blood pressure: Women with hypertension generally can 
use DMPA (U.S. MEC 2), with the exception of women with 
severe hypertension or vascular disease, who generally should 
not use DMPA (U.S. MEC 3) (5). Screening for hypertension 
before initiation of DMPA is not necessary because of the 
low prevalence of undiagnosed severe hypertension and the 
high likelihood that women with these conditions already 
would have had them diagnosed. A systematic review did 
not identify any evidence regarding outcomes among women 
who were screened versus not screened with a blood pressure 
measurement before initiation of progestin-only contraceptives 
(21). The prevalence of undiagnosed hypertension among 
women of reproductive age is low. During 1999–2008 among 
women aged 20–44 years in the United States, the percentage 
with diagnosed hypertension was 7.8%, and the percentage 
with undiagnosed hypertension was 1.9% (144).
Glucose: Although women with complicated diabetes 
generally should not use DMPA (U.S. MEC 3) (5), screening 
for diabetes before initiation of DMPA is not necessary because 
of the low prevalence of undiagnosed diabetes and the high 
likelihood that women with complicated diabetes would 
already have had the condition diagnosed. A systematic review 
did not identify any evidence regarding outcomes among 
women who were screened versus not screened with glucose 
measurement before initiation of hormonal contraceptives 
(14). The prevalence of diabetes among women of reproductive 
age is low. During 1999–2008 among women aged 20–44 years 
TABLE 4. Classification of examinations and tests needed before 
DMPA initiation
Examination or test Class*
Examination
Blood pressure C
Weight (BMI) (weight [kg]/height [m]2) —†
Clinical breast examination C







Cervical cytology (Papanicolaou smear) C
STD screening with laboratory tests C
HIV screening with laboratory tests C
Abbreviations: BMI = body mass index; DMPA = depot medroxyprogesterone 
acetate; HIV  =  human immunodeficiency virus; STD  =  sexually transmitted 
disease; U.S. MEC = U.S. Medical Eligibility Criteria for Contraceptive Use, 2010.
* Class A: essential and mandatory in all circumstances for safe and effective 
use of the contraceptive method. Class B: contributes substantially to safe and 
effective use, but implementation may be considered within the public health 
and/or service context; the risk of not performing an examination or test should 
be balanced against the benefits of making the contraceptive method 
available. Class C: does not contribute substantially to safe and effective use 
of the contraceptive method.
† Weight (BMI) measurement is not needed to determine medical eligibility for 
any methods of contraception because all methods can be used (U.S. MEC 1) or 
generally can be used (U.S. MEC 2) among obese women (Box 2). However, 
measuring weight and calculating BMI at baseline might be helpful for 
monitoring any changes and counseling women who might be concerned about 
weight change perceived to be associated with their contraceptive method. 
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in the United States, the percentage with diagnosed diabetes 
was 3% and the percentage with undiagnosed diabetes was 
0.5% (144). Although hormonal contraceptives can have some 
adverse effects on glucose metabolism in healthy and diabetic 
women, the overall clinical effect is minimal (145–151).
Liver enzymes: Although women with certain liver diseases 
generally should not use DMPA (U.S. MEC 3) (5), screening 
for liver disease before initiation of DMPA is not necessary 
because of the low prevalence of these conditions and the high 
likelihood that women with liver disease already would have 
had the condition diagnosed. A systematic review did not 
identify any evidence regarding outcomes among women who 
were screened versus not screened with liver enzyme tests before 
initiation of hormonal contraceptives (14). The prevalence of 
liver disorders among women of reproductive age is low. In 2008 
among adults aged 18–44 years, the percentage with liver disease 
(not further specified) was 1.0% (90). In 2009, the incidence of 
acute hepatitis A, B, or C among women was <1 per 100,000 
population (91). During 1998–2007, the incidence of liver 
carcinoma among women was approximately 3 per 100,000 
population (92). Because estrogen and progestins are metabolized 
in the liver, the use of hormonal contraceptives among women 
with liver disease might, theoretically, be a concern. The use of 
hormonal contraceptives, specifically COCs and POPs, does not 
affect disease progression or severity in women with hepatitis, 
cirrhosis, or benign focal nodular hyperplasia (93,94), although 
evidence is limited and no evidence exists for DMPA.
Clinical breast examination: Although women with current 
breast cancer should not use DMPA (U.S. MEC 4) (5), screening 
asymptomatic women with a clinical breast examination before 
initiating DMPA is not necessary because of the low prevalence 
of breast cancer among women of reproductive age. A systematic 
review did not identify any evidence regarding outcomes 
among women who were screened versus not screened with 
a clinical breast examination before initiation of hormonal 
contraceptives (15). The incidence of breast cancer among 
women of reproductive age in the United States is low. In 2009, 
the incidence of breast cancer among women aged 20–49 years 
was approximately 72 per 100,000 women (95).
Other screening: Women with hyperlipidemia, anemia, 
thrombogenic mutations, cervical intraepithelial neoplasia, 
cervical cancer, HIV infection, or other STDs can use 
(U.S. MEC 1) or generally can use (U.S. MEC 2) DMPA (5); 
therefore, screening for these conditions is not necessary for 
the safe initiation of DMPA.
Routine Follow-Up After Injectable 
Initiation
These recommendations address when routine follow-up 
is recommended for safe and effective continued use of 
contraception for healthy women. The recommendations refer 
to general situations and might vary for different users and 
different situations. Specific populations that might benefit 
from more frequent follow-up visits include adolescents, those 
with certain medical conditions or characteristics, and those 
with multiple medical conditions.
•	 Advise	a	woman	to	return	at	any	time	to	discuss	side	effects	
or other problems, if she wants to change the method 
being used, and when it is time for reinjection. No routine 
follow-up visit is required.
•	 At	 other	 routine	 visits,	 health-care	 providers	 seeing	
injectable users should do the following:
 – Assess the woman’s satisfaction with her contraceptive method 
and whether she has any concerns about method use.
 – Assess any changes in health status, including 
medications, that would change the appropriateness of 
the injectable for safe and effective continued use based 
on U.S. MEC (e.g., category 3 and 4 conditions and 
characteristics).
 – Consider assessing weight changes and counseling women 
who are concerned about weight changes perceived to be 
associated with their contraceptive method.
Comments and Evidence Summary. Although no evidence 
exists regarding whether a routine follow-up visit after initiating 
DMPA improves correct or continued use, monitoring weight 
or BMI change over time is important for DMPA users.
A systematic review identified a limited body of evidence that 
examined whether weight gain in the few months after DMPA 
initiation predicted future weight gain (17). Two studies found 
significant differences in weight gain or BMI at follow-up 
periods ranging from 12 to 36 months between early weight 
gainers (i.e., those who gained >5% of their baseline body 
weight within 6 months after initiation) and those who were 
not early weight gainers (152,153). The differences between 
groups were more pronounced at 18, 24, and 36 months 
than at 12 months. One study found that most adolescent 
DMPA users who had gained >5% of their baseline weight by 
3 months gained even more weight by 12 months (154) (Level 
of evidence: II-2, fair, to II-3, fair, direct).










late (15 weeks from the last injection) without requiring 
additional contraceptive protection.
•	 If	the	woman	is	>2	weeks	late	(>15	weeks	from	the	last	injection)	
for a repeat DMPA injection, she can have the injection if it is 
reasonably certain that she is not pregnant (Box 1). She needs to 
abstain from sexual intercourse or use additional contraceptive 
protection for the next 7 days. She might consider the use of 
emergency contraception if appropriate.
Comments and Evidence Summary. There are no time 
limits on early injections; injections can be given when 
necessary (e.g., when a woman cannot return at the routine 
interval). WHO has extended the time that a woman can 
have a late reinjection (i.e., grace period) for DMPA use from 
2 weeks to 4 weeks on the basis of data from one study showing 
low pregnancy rates through 4 weeks; however, the CDC 
expert group did not consider the data to be generalizable to 
the United States because a large proportion of women in the 
study were breastfeeding. Therefore, U.S. SPR recommends 
a grace period of 2 weeks.
A systematic review identified 12 studies evaluating time to 
pregnancy or ovulation after the last injection of DMPA (155). 
Although pregnancy rates were low during the 2-week interval 
following the reinjection date and for 4 weeks following the 
reinjection date, data were sparse and one study included a 
large proportion of breastfeeding women (156–158). Studies 
also indicated a wide variation in time to ovulation after the 
last DMPA injection, with the majority ranging from 15 to 
49 weeks from the last injection (159–167) (Level of evidence: 
II-2, fair, direct).
Bleeding Irregularities (Including 
Amenorrhea) During Injectable Use
•	 Before	DMPA	 initiation,	 provide	 counseling	 about	
potential changes in bleeding patterns during DMPA use. 
Amenorrhea and unscheduled spotting or light bleeding 
is common with DMPA use, and heavy or prolonged 
bleeding can occur with DMPA use. These bleeding 
irregularities are generally not harmful and might decrease 
with continued DMPA use.
Unscheduled Spotting or Light Bleeding
•	 If	clinically	indicated,	consider	an	underlying	gynecological	
problem, such as interactions with other medications, an 
STD, pregnancy, or new pathologic uterine conditions 
(e.g., polyps or fibroids). If an underlying gynecological 
problem is found, treat the condition or refer for care.
•	 If	an	underlying	gynecologic	problem	is	not	found	and	
the woman wants treatment, the following treatment 
option during days of bleeding can be considered:
 – NSAIDs for short-term treatment (5–7 days)
•	 If	unscheduled	 spotting	or	 light	bleeding	persists	and	 the	
woman finds it unacceptable, counsel her on alternative 
contraceptive methods, and offer another method if it is desired.
Heavy or Prolonged Bleeding
•	 If	clinically	indicated,	consider	an	underlying	gynecological	
problem, such as interactions with other medications, an 
STD, pregnancy, or new pathologic uterine conditions 
(such as fibroids or polyps). If an underlying gynecologic 
problem is identified, treat the condition or refer for care.
•	 If	an	underlying	gynecologic	problem	is	not	found	and	
the woman wants treatment, the following treatment 
options during days of bleeding can be considered:
 – NSAIDS for short-term treatment (5–7 days)
 – Hormonal treatment (if medically eligible) with low-
dose COCs or estrogen for short-term treatment 
(10–20 days)
•	 If	heavy	or	prolonged	bleeding	persists	and	the	woman	finds	
it unacceptable, counsel her on alternative contraceptive 
methods, and offer another method if it is desired.
Amenorrhea
•	 Amenorrhea	 does	 not	 require	 any	medical	 treatment.	
Provide reassurance.
 – If a woman’s regular bleeding pattern changes abruptly 
to amenorrhea, consider ruling out pregnancy if 
clinically indicated.
•	 If	amenorrhea	persists	and	the	woman	finds	it	unacceptable,	
counsel her on alternative contraceptive methods, and 
offer another method if it is desired.
Comments and Evidence Summary. During contraceptive 
counseling and before initiation of DMPA, information 
about common side effects such as irregular bleeding should 
be discussed. Unscheduled bleeding or spotting is common 
with DMPA use (168). Additionally, amenorrhea is common 
after ≥1 years of continuous use (168,169). These bleeding 
irregularities are generally not harmful. Enhanced counseling 
among DMPA users detailing expected bleeding patterns and 
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reassurance that these irregularities generally are not harmful 
has been shown to reduce DMPA discontinuation in clinical 
trials (101,102).
A systematic review, as well as two additional studies, 
examined the treatment of bleeding irregularities during 
DMPA use (122,170,171). Two small studies found significant 
cessation of bleeding within 7 days of starting treatment 
among women taking valdecoxib for 5 days or mefenamic 
acid for 5 days compared with placebo (172,173). Treatment 
with ethinyl estradiol was found to stop bleeding better 
than placebo during the treatment period, although rates 
of discontinuation were high, and safety outcomes were not 
examined (174). In one small study among DMPA users who 
had been experiencing amenorrhea for 2 months, treatment 
with COCs was found to alleviate amenorrhea better than 
placebo (175). No studies examined the effects of aspirin on 
bleeding irregularities among DMPA users.
Combined Hormonal Contraceptives
Combined hormonal contraceptives contain both estrogen 
and a progestin and include 1) COCs (various formulations), 
2) a transdermal contraceptive patch (which releases 150 µg 
of norelgestromin and 20 µg ethinyl estradiol daily), and 
3) a vaginal contraceptive ring (which releases 120 µg 
etonogestrel and 15 µg ethinyl estradiol daily). Approximately 
9 out of 100 women become pregnant in the first year of use 
with combined hormonal contraceptives with typical use (59). 
These methods are reversible and can be used by women of all 
ages. Combined hormonal contraceptives are generally used for 
21–24 consecutive days, followed by 4–7 hormone-free days 
(either no use or placebo pills). These methods are sometimes 
used for an extended period with infrequent or no hormone-
free days. Combined hormonal contraceptives do not protect 
against STDs; consistent and correct use of male latex condoms 
reduces the risk for STDs, including HIV.
Initiation of Combined Hormonal 
Contraceptives
Timing
•	 Combined	hormonal	 contraceptives	 can	be	 initiated	 at	
any time if it is reasonably certain that the woman is not 
pregnant (Box 1).
Need for Back-Up Contraception
•	 If	combined	hormonal	contraceptives	are	started	within	
the first 5 days since menstrual bleeding started, no 
additional contraceptive protection is needed.
•	 If	combined	hormonal	contraceptives	are	started	>5	days	
since menstrual bleeding started, the woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
Special Considerations
Amenorrhea (Not Postpartum)
•	Timing: Combined hormonal contraceptives can be 
started at any time if it is reasonably certain that the 
woman is not pregnant (Box 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 7 days.
Postpartum (Breastfeeding)
•	Timing: Combined hormonal contraceptives can be started 
when the woman is medically eligible to use the method (176) 
and if it is reasonably certain that she is not pregnant. (Box 1).
 – Postpartum women who are breastfeeding should not use 
combined hormonal contraceptives during the first 
3 weeks after delivery (U.S. MEC 4) because of concerns 
about increased risk for venous thromboembolism and 
generally should not use combined hormonal contraceptives 
during the fourth week postpartum (U.S. MEC 3) because 
of concerns about potential effects on breastfeeding 
performance. Postpartum, breastfeeding women with 
other risk factors for venous thromboembolism generally 
should not use combined hormonal contraceptives 4–6 
weeks after delivery (U.S. MEC 3).
•	Need for back-up contraception: If the woman is 
<6 months postpartum, amenorrheic, and fully or nearly 
fully breastfeeding (exclusively breastfeeding or the vast 
majority [≥85%] of feeds are breastfeeds) (60), no 
additional contraceptive protection is needed. Otherwise, 
a woman who is ≥21 days postpartum and has not 
experienced return of her menstrual cycle needs to abstain 
from sexual intercourse or use additional contraceptive 
protection for the next 7 days. If her menstrual cycles have 
returned and it has been >5 days since menstrual bleeding 
started, she needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 7 days.
Postpartum (Not Breastfeeding)
•	Timing: Combined hormonal contraceptives can be started 
when the woman is medically eligible (176) and if it is 
reasonably certain that she is not pregnant (Box 1).
 – Postpartum women should not use combined hormonal 
contraceptives during the first 3 weeks after delivery 
(U.S. MEC 4) because of concerns about increased risk 
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for venous thromboembolism. Postpartum women with 
other risk factors for venous thromboembolism 
generally should not use combined hormonal 
contraceptives 3–6 weeks after delivery (U.S. MEC 3).
•	Need for back-up contraception: A woman who is ≥21 
days postpartum and whose menstrual cycles have not 
returned needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 7 days. If 
her menstrual cycles have returned and it has been >5 days 
since menstrual bleeding started, she needs to abstain from 
sexual intercourse or use additional contraceptive 
protection for the next 7 days.
Postabortion (Spontaneous or Induced)
•	Timing: Combined hormonal contraceptives can be started 
within the first 7 days after first or second trimester abortion, 
including immediately postabortion (U.S. MEC 1).
•	Need for back-up contraception: She needs to abstain 
from sexual intercourse or use additional contraceptive 
protection for the next 7 days unless combined hormonal 
contraceptives are started at the time of a surgical abortion.
Switching from Another Contraceptive Method
•	Timing: Combined hormonal contraceptives can be 
started immediately if it is reasonably certain that the 
woman is not pregnant (Box 1). Waiting for her next 
menstrual period is unnecessary.
•	Need for back-up contraception: If it has been >5 days 
since menstrual bleeding started, she needs to abstain from 
sexual intercourse or use additional contraceptive 
protection for the next 7 days.
•	 Switching from an IUD: If the woman has had sexual 
intercourse since the start of her current menstrual cycle and 
it has been >5 days since menstrual bleeding started, 
theoretically, residual sperm might be in the genital tract, 
which could lead to fertilization if ovulation occurs. A health-
care provider may consider any of the following options:
 – Advise the women to retain the IUD for at least 7 days 
after combined hormonal contraceptives are initiated 
and return for IUD removal.
 – Advise the woman to abstain from sexual intercourse 
or use barrier contraception for 7 days before removing 
the IUD and switching to the new method.
 – Advise the woman to use ECPs at the time of IUD removal.
Comments and Evidence Summary. In situations in which 
the health-care provider is uncertain whether the woman 
might be pregnant, the benefits of starting combined hormonal 
contraceptives likely exceed any risk; therefore, starting 
combined hormonal contraceptives should be considered at 
any time, with a follow-up pregnancy test in 2–4 weeks. If a 
woman needs to use additional contraceptive protection when 
switching to combined hormonal contraceptives from another 
contraceptive method, consider continuing her previous method 
for 7 days after starting combined hormonal contraceptives.
A systematic review of 18 studies examined the effects of 
starting combined hormonal contraceptives on different days 
of the menstrual cycle (22). Overall, the evidence suggested 
that pregnancy rates did not differ by the timing of combined 
hormonal contraceptive initiation (143,177–179) (Level of 
evidence: I to II-3, fair, indirect). The more follicular activity that 
occurred before starting COCs, the more likely ovulation was to 
occur; however, no ovulations occurred when COCs were started 
at a follicle diameter of 10 mm (mean cycle day 7.6) or when the 
ring was started at 13 mm (median cycle day 11) (180–189) (Level 
of evidence: I to II-3, fair, indirect). Bleeding patterns and other 
side effects did not vary with the timing of combined hormonal 
contraceptive initiation (177,178,190–194) (Level of evidence: 
I to II-2, good to poor, direct). Although continuation rates of 
combined hormonal contraceptives were initially improved by 
the “quick start” approach (i.e., starting on the day of the visit), 
the advantage disappeared over time (178,179,190–195) (Level 
of evidence: I to II-2, good to poor, direct).
Examinations and Tests Needed Before 
Initiation of Combined Hormonal 
Contraceptives
Among healthy women, few examinations or tests are 
needed before initiation of combined hormonal contraceptives 
(Table 5). Blood pressure should be measured before initiation 
of combined hormonal contraceptives. Baseline weight 
and BMI measurements might be useful for monitoring 
combined hormonal contraceptive users over time. Women 
with known medical problems or other special conditions 
might need additional examinations or tests before being 
determined to be appropriate candidates for a particular 
method of contraception. U.S. MEC might be useful in such 
circumstances (5).
Comments and Evidence Summary. Blood pressure: 
Women who have more severe hypertension (systolic pressure 
of ≥160 mm Hg or diastolic pressure of ≥100 mm Hg) 
or vascular disease should not use combined hormonal 
contraceptives (U.S. MEC 4), and women who have less 
severe hypertension (systolic pressure of 140–159 mm Hg or 
diastolic pressure of 90–99 mm Hg) or adequately controlled 
hypertension generally should not use combined hormonal 
contraceptives (U.S. MEC 3) (5). Therefore, blood pressure 
should be measured before initiating combined hormonal 
contraceptives. If access to health care is limited, blood pressure 
measurements may be obtained in nonclinical settings, such as 
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pharmacies or fire stations, and reported by the woman to her 
provider. Evidence suggests that cardiovascular outcomes are 
worse among women who did not have their blood pressure 
measured before initiating COCs.
A systematic review identified six articles from three studies 
that reported cardiovascular outcomes among women who had 
blood pressure measurements and women who did not have 
blood pressure measurements before initiating COCs (21). 
Three case-control studies showed that women who did not 
have blood pressure measurements before initiating COCs 
had a higher risk for acute myocardial infarction than women 
who did have blood pressure measurements (196–198). Two 
case-control studies showed that women who did not have 
blood pressure measurements before initiating COCs had 
a higher risk for ischemic stroke than women who did have 
blood pressure measurements (199,200). One case-control 
study showed no difference in the risk for hemorrhagic stroke 
among women who initiated COCs regardless of whether their 
blood pressure was measured (201). Studies that examined 
hormonal contraceptive methods other than COCs were not 
identified (Level of evidence: II-2, fair, direct).
Weight (BMI): Obese women generally can use combined 
hormonal contraceptives (U.S. MEC 2) (5); therefore, 
screening for obesity is not necessary for the safe initiation 
of combined hormonal contraceptives. However, measuring 
weight and calculating BMI at baseline might be helpful for 
monitoring any changes and counseling women who might 
be concerned about weight change perceived to be associated 
with their contraceptive method.
Bimanual examination and cervical inspection: Pelvic 
examination is not necessary before initiation of combined 
hormonal contraceptives because it does not facilitate detection 
of conditions for which hormonal contraceptives would be 
unsafe. Women with certain conditions such as current breast 
cancer, severe hypertension or vascular disease, heart disease, 
migraine headaches with aura, and certain liver diseases, as well 
as women aged ≥35 years who smoke ≥15 cigarettes per day, 
should not use (U.S. MEC 4) or generally should not use (U.S. 
MEC 3) combined hormonal contraceptives (5); however, none 
of these conditions are likely to be detected by pelvic examination 
(120). A systematic review identified two case-control studies 
that compared delayed and immediate pelvic examination 
before initiation of hormonal contraceptives, specifically oral 
contraceptives or DMPA (15). No differences in risk factors for 
cervical neoplasia, incidence of STDs, incidence of abnormal 
Papanicolaou smears, or incidence of abnormal wet mounts were 
found (Level of evidence: II-2 fair, direct).
Glucose: Although women with complicated diabetes 
should not use (U.S. MEC 4) or generally should not use 
(U.S. MEC 3) combined hormonal contraceptives, depending 
on the severity of the condition (5), screening for diabetes 
before initiation of hormonal contraceptives is not necessary 
because of the low prevalence of undiagnosed diabetes and the 
high likelihood that women with complicated diabetes already 
would have had the condition diagnosed. A systematic review 
did not identify any evidence regarding outcomes among 
women who were screened versus not screened with glucose 
measurement before initiation of hormonal contraceptives 
(14). The prevalence of diabetes among women of reproductive 
age is low. During 1999–2008 among women aged 20–44 years 
in the United States, the percentage with diagnosed diabetes 
was 3% and the percentage with undiagnosed diabetes was 
0.5% (144). Although hormonal contraceptives can have some 
adverse effects on glucose metabolism in healthy and diabetic 
women, the overall clinical effect is minimal (145–151).
Lipids: Although some women with hyperlipidemias 
generally should not use combined hormonal contraceptives 
(U.S. MEC 2/3, depending on the type and severity of the 
hyperlipidemia and presence of other cardiovascular risk 
factors) (5), screening for hyperlipidemia before initiation of 
TABLE 5. Classification of examinations and tests needed before 
combined hormonal contraceptive initiation
Examination or laboratory test Class*
Examination
Blood pressure A†
Weight (BMI) (weight [kg]/height [m]2) —§
Clinical breast examination C







Cervical cytology (Papanicolaou smear) C
STD screening with laboratory tests C
HIV screening with laboratory tests C
Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; 
STD = sexually transmitted disease; U.S. MEC = U.S. Medical Eligibility Criteria for 
Contraceptive Use, 2010.
* Class A: essential and mandatory in all circumstances for safe and effective 
use of the contraceptive method. Class B: contributes substantially to safe and 
effective use, but implementation may be considered within the public health 
and/or service context; the risk of not performing an examination or test should 
be balanced against the benefits of making the contraceptive method 
available. Class C: does not contribute substantially to safe and effective use 
of the contraceptive method.
† In cases in which access to health care might be limited, the blood pressure 
measurement can be obtained by the woman in a nonclinical setting (e.g., 
pharmacy or fire station) and self-reported to the provider.
§ Weight (BMI) measurement is not needed to determine medical eligibility for 
any methods of contraception because all methods can be used (U.S. MEC 1) or 
generally can be used (U.S. MEC 2) among obese women (Box 2). However, 
measuring weight and calculating BMI at baseline might be helpful for 
monitoring any changes and counseling women who might be concerned about 
weight change perceived to be associated with their contraceptive method.
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hormonal contraceptives is not necessary because of the low 
prevalence of undiagnosed disease in women of reproductive 
age and the low likelihood of clinically significant changes 
with use of hormonal contraceptives. A systematic review 
did not identify any evidence regarding outcomes among 
women who were screened versus not screened with lipid 
measurement before initiation of hormonal contraceptives 
(14). The prevalence of hyperlipidemia among women of 
reproductive age is low. During 1999–2008 among women 
aged 20–44 years in the United States, approximately 10% 
had hypercholesterolemia, defined as total cholesterol 
≥ 240 mg/dL or currently taking lipid-lowering medications, 
and the prevalence of undiagnosed hypercholesterolemia was 
approximately 2% (144). Studies have shown mixed results 
about the effects of hormonal methods on lipid levels, and the 
clinical significance of these changes is unclear (202–204). In 
addition, women with abnormal lipid levels at baseline were 
not found to have increased risk for adverse changes to their 
lipid profile when using hormonal methods (202).
Liver enzymes: Although women with certain liver 
diseases should not use (U.S. MEC 4) or generally should 
not use (U.S. MEC 3) combined hormonal contraceptives 
(5), screening for liver disease before initiation of combined 
hormonal contraceptives is not necessary because of the low 
prevalence of these conditions and the high likelihood that 
women with liver disease already would have had the condition 
diagnosed. A systematic review did not identify any evidence 
regarding outcomes among women who were screened versus 
not screened with liver enzyme tests before initiation of 
hormonal contraceptives (14). The prevalence of liver disorders 
among women of reproductive age is low. In 2008 among 
adults aged 18–44 years, the percentage with liver disease (not 
further specified) was 1.0% (90). In 2009, the incidence of 
acute hepatitis A, B, or C among women was <1 per 100,000 
population (91). During 1998–2007, the incidence of liver 
carcinoma among women was approximately 3 per 100,000 
population (92). Because estrogen and progestins are 
metabolized in the liver, the use of hormonal contraceptives 
among women with liver disease might, theoretically, be a 
concern. The use of hormonal contraceptives, specifically 
COCs and POPs, does not affect disease progression or severity 
in women with hepatitis, cirrhosis, or benign focal nodular 
hyperplasia (93,94), although evidence is limited; no evidence 
exists for other types of combined hormonal contraceptives.
Thrombogenic mutations: Women with thrombogenic 
mutations should not use combined hormonal contraceptives 
(U.S. MEC 4) (5) because of the increased risk for venous 
thromboembolism (205). However, studies have shown 
that universal screening for thrombogenic mutations before 
initiating COCs is not cost-effective because of the rarity of 
the conditions and the high cost of screening (206–208).
Clinical breast examination: Although women with 
current breast cancer should not use combined hormonal 
contraceptives (U.S. MEC 4) (5), screening asymptomatic 
women with a clinical breast examination before initiating 
combined hormonal contraceptives is not necessary because 
of the low prevalence of breast cancer among women of 
reproductive age. A systematic review did not identify any 
evidence regarding outcomes among women who were 
screened versus not screened with a breast examination before 
initiation of hormonal contraceptives (15). The incidence of 
breast cancer among women of reproductive age in the United 
States is low. In 2009, the incidence of breast cancer among 
women aged 20–49 years was approximately 72 per 100,000 
women (95).
Other screening: Women with anemia, cervical intraepithelial 
neoplasia, cervical cancer, HIV infection, or other STDs can 
use (U.S. MEC 1) or generally can use (U.S. MEC 2) combined 
hormonal contraceptives (5); therefore, screening for these 
conditions is not necessary for the safe initiation of combined 
hormonal contraceptives.
Number of Pill Packs that Should Be 
Provided at Initial and Return Visits
•	 At	the	initial	and	return	visits,	provide	or	prescribe	up	to	a	
1-year supply of COCs (e.g., 13 28-day pill packs), 
depending on the woman’s preferences and anticipated use.
•	 A	woman	should	be	able	to	obtain	COCs	easily	 in	the	
amount and at the time she needs them.
Comments and Evidence Summary. The more pill packs 
given up to 13 cycles, the higher the continuation rates. 
Restricting the number of pill packs distributed or prescribed 
can result in unwanted discontinuation of the method and 
increased risk for pregnancy.
A systematic review of the evidence suggested that providing 
a greater number of pill packs was associated with increased 
continuation (23). Studies that compared provision of one 
versus 12 packs, one versus 12 or 13 packs, or three versus seven 
packs found increased continuation of pill use among women 
provided with more pill packs (209–211). However, one study 
found that there was no difference in continuation when patients 
were provided one and then three packs versus four packs all at 
once (212). In addition to continuation, a greater number of 
pills packs provided was associated with fewer pregnancy tests, 
fewer pregnancies, and lower cost per client. However, a greater 
number of pill packs (i.e., 13 packs versus three packs) also was 
associated with increased pill wastage in one study (210) (Level 
of evidence: I to II-2, fair, direct).
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Routine Follow-Up After Combined 
Hormonal Contraceptive Initiation
These recommendations address when routine follow-up 
is recommended for safe and effective continued use of 
contraception for healthy women. The recommendations refer 
to general situations and might vary for different users and 
different situations. Specific populations that might benefit 
from more frequent follow-up visits include adolescents, those 
with certain medical conditions or characteristics, and those 
with multiple medical conditions.
•	 Advise	a	woman	to	return	at	any	time	to	discuss	side	effects	
or other problems or if she wants to change the method 
being used. No routine follow-up visit is required.
•	 At	other	routine	visits,	health-care	providers	seeing	combined	
hormonal contraceptive users should do the following:
 – Assess the woman’s satisfaction with her contraceptive 
method and whether she has any concerns about 
method use.
 – Assess any changes in health status, including 
medications, that would change the appropriateness of 
combined hormonal contraceptives for safe and 
effective continued use based on U.S. MEC (e.g., 
category 3 and 4 conditions and characteristics).
 – Assess blood pressure.
 – Consider assessing weight changes and counseling women 
who are concerned about weight changes perceived to be 
associated with their contraceptive method.
Comments and Evidence Summary. No evidence exists 
regarding whether a routine follow-up visit after initiating combined 
hormonal contraceptives improves correct or continued use. 
Monitoring blood pressure is important for combined hormonal 
contraceptive users. Health-care providers might consider 
recommending women obtain blood pressure measurements in 
nonclinical settings (e.g., pharmacy or fire station).
A systematic review identified five studies that examined the 
incidence of hypertension among women who began using 
a COC versus those who started a nonhormonal method 
of contraception or a placebo (17). Few women developed 
hypertension after initiating COCs, and studies examining 
increases in blood pressure after COC initiation found mixed 
results. No studies were identified that examined changes in 
blood pressure among patch or vaginal ring users (Level of 
evidence: I, fair, to II-2, fair, indirect).
Late or Missed Doses and Side Effects from 
Combined Hormonal Contraceptive Use
For the following recommendations, a dose is considered 
late when <24 hours have elapsed since the dose should have 
been taken. A dose is considered missed if ≥24 hours have 
elapsed since the dose should have been taken. For example, 
if a COC pill was supposed to have been taken on Monday at 
9:00 a.m. and is taken at 11:00 a.m., the pill is late; however, 
by Tuesday morning at 11:00 a.m., Monday’s 9:00 a.m. pill 
has been missed and Tuesday’s 9:00 a.m. pill is late. For COCs, 
the recommendations only apply to late or missed hormonally 
active pills and not to placebo pills. Recommendations are 
provided for late or missed pills (Figure 2), the patch (Figure 3), 
and the ring (Figure 4).
Comments and Evidence Summary. Inconsistent or 
incorrect use of combined hormonal contraceptives is a major 
cause of combined hormonal contraceptive failure. Extending 
the hormone-free interval is considered to be a particularly risky 
time to miss combined hormonal contraceptives. Seven days of 
continuous combined hormonal contraceptive use is deemed 
necessary to reliably prevent ovulation. The recommendations 
reflect a balance between simplicity and precision of science. 
Women who frequently miss COCs or experience other usage 
errors with combined hormonal patch or combined vaginal 
ring should consider an alternative contraceptive method 
that is less dependent on the user to be effective (e.g., IUD, 
implant, or injectable).
A systematic review identified 36 studies that examined 
measures of contraceptive effectiveness of combined hormonal 
contraceptives during cycles with extended hormone-free 
intervals, shortened hormone-free intervals, or deliberate 
nonadherence on days not adjacent to the hormone-free 
interval (24). Most of the studies examined COCs (188,213–
240), two examined the combined hormonal patch (234,241), 
and six examined the combined vaginal ring (185,242–246). 
No direct evidence on the effect of missed pills on the risk 
for pregnancy was found. Studies of women deliberately 
extending the hormone-free interval up to 14 days found 
wide variability in the amount of follicular development and 
occurrence of ovulation (216,219,221,222,224,225,227–230); 
in general, the risk for ovulation was low, and among women 
who did ovulate, cycles were usually abnormal. In studies of 
women who deliberately missed pills on various days during 
the cycle not adjacent to the hormone-free interval, ovulation 
occurred infrequently (214,220–222,230,231,233,234). 
Studies comparing 7-day hormone-free intervals with shorter 
hormone-free intervals found lower rates of pregnancy 
(213,217,226,232) and significantly greater suppression of 
ovulation (215,225,236–238,240) among women with shorter 
intervals in all but one study (235), which found no difference. 
Two studies that compared 30-µg ethinyl estradiol  pills with 
20-µg ethinyl estradiol  pills showed more follicular activity 
when 20-µg ethinyl estradiol  pills were missed (216,219). In 
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studies examining the combined vaginal ring, three studies 
found that nondeliberate extension of the hormone-free 
interval for 24 to <48 hours from the scheduled period 
did not increase the risk for pregnancy (242,243,245); one 
study found that ring insertion after a deliberately extended 
hormone-free interval that allowed a 13-mm follicle to develop 
interrupted ovarian function and further follicular growth 
(185); and one study found that inhibition of ovulation was 
maintained after deliberately forgetting to remove the ring 
for up to 2 weeks after normal ring use (246). In studies 
examining the combined hormonal patch, one study found 
that missing 1–3 consecutive days before patch replacement 
(either wearing one patch 3 days longer before replacement 
or going 3 days without a patch before replacing the next 
patch) on days not adjacent to the patch-free interval resulted 
in little follicular activity and low risk for ovulation (234), 
and one pharmacokinetic study found that serum levels of 
ethinyl estradiol and progestin norelgestromin remained within 
reference ranges after extending patch wear for 3 days (241). 
No studies were found on extending the patch-free interval. In 
studies that provide indirect evidence on the effects of missed 
combined hormonal contraception on surrogate measures of 
pregnancy, how differences in surrogate measures correspond 
to pregnancy risk is unclear (Level of evidence: I, good, indirect 
to II-3, poor, direct).
Vomiting or Severe Diarrhea While Using COCs
Certain steps should be taken by women who experience 
vomiting or severe diarrhea while using COCs (Figure 5).
Comments and Evidence Summary. Theoretically, the 
contraceptive effectiveness of COCs might be decreased because 
of vomiting or severe diarrhea. Because of the lack of evidence 
that addresses vomiting or severe diarrhea while using COCs, 
these recommendations are based on the recommendations 
FIGURE 2. Recommended actions after late or missed combined oral contraceptives
If one hormonal pill is late: 
(<24 hours since a pill 
should have been taken)
If one hormonal pill has been 
missed: (24 to <48 hours since a 
pill should have been taken)
If two or more consecutive hormonal 
pills have been missed: (≥48 hours since 
a pill should have been taken)
• Take the late or missed pill as   
 soon as possible.
• Continue taking the remaining  
 pills at the usual time (even if it  
 means taking two pills on the   
 same day).
• No additional contraceptive   
 protection is needed.
• Emergency contraception is not  
 usually needed but can be   
 considered if hormonal pills   
 were missed earlier in the cycle  
 or in the last week of the   
 previous cycle.
• Take the most recent missed pill as  
 soon as possible. (Any other missed  
 pills should be discarded.)
• Continue taking the remaining pills at  
 the usual time (even if it means taking  
 two pills on the same day).
• Use back-up contraception (e.g.,  
 condoms) or avoid sexual intercourse  
 until hormonal pills have been taken  
 for 7 consecutive days.
• If pills were missed in the last week of  
 hormonal pills (e.g., days 15–21 for  
 28-day pill packs):
 — Omit the hormone-free interval by  
   nishing the hormonal pills in the  
   current pack and starting a new  
   pack the next day.
 — If unable to start a new pack  
   immediately, use back-up   
   contraception (e.g., condoms) or  
   avoid sexual intercourse until  
   hormonal pills from a new pack  
   have been taken for 7 consecutive  
   days.
• Emergency contraception should be  
 considered if hormonal pills were  
 missed during the rst week and  
 unprotected sexual intercourse  
 occurred in the previous 5 days.
• Emergency contraception may also  
 be considered at other times as  
 appropriate.
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for missed COCs. No evidence was found on the effects of 
vomiting or diarrhea on measures of contraceptive effectiveness 
including pregnancy, follicular development, hormone levels, 
or cervical mucus quality.
Unscheduled Bleeding with Extended or 
Continuous Use of Combined  
Hormonal Contraceptives
•	 Before	initiation	of	combined	hormonal	contraceptives,	
provide counseling about potential changes in bleeding 
patterns during extended or continuous combined 
hormonal contraceptive use. (Extended contraceptive use 
is defined as a planned hormone-free interval after at least 
two contiguous cycles. Continuous contraceptive use is 
defined as uninterrupted use of hormonal contraception 
without a hormone-free interval [247].)
•	 Unscheduled	spotting	or	bleeding	is	common	during	the	
first 3–6 months of extended or continuous combined 
hormonal contraceptive use. It is generally not harmful 
and decreases with continued combined hormonal 
contraceptive use.
•	 If	clinically	indicated,	consider	an	underlying	gynecological	
problem, such as inconsistent use, interactions with other 
medications, cigarette smoking, an STD, pregnancy, or 
new pathologic uterine conditions (e.g., polyps or 
fibroids). If an underlying gynecological problem is found, 
treat the condition or refer for care.
•	 If	an	underlying	gynecological	problem	is	not	found	and	
the woman wants treatment, the following treatment 
option can be considered:
 – Advise the woman to discontinue combined hormonal 
contraceptive use (i.e., a hormone-free interval) for 3–4 
consecutive days; a hormone-free interval is not 
recommended during the first 21 days of using the 
continuous or extended combined hormonal 
contraceptive method. A hormone-free interval also is 
not recommended more than once per month because 
contraceptive effectiveness might be reduced.
•	 If	unscheduled	spotting	or	bleeding	persists	and	the	woman	
finds it unacceptable, counsel her on alternative contraceptive 
methods, and offer another method if it is desired.
Comments and Evidence Summary. During contraceptive 
counseling and before initiating extended or continuous 
FIGURE 3. Recommended actions after delayed application or detachment with combined hormonal patch
Delayed application or detachment* for <48 
hours since a patch should have been applied 
or reattached
Delayed application or detachment* for ≥48 
hours since a patch should have been applied 
or reattached
• Apply a new patch as soon as possible. (If   
 detachment occured <24 hours since the   
 patch was applied, try to reapply the patch  
 or replace with a new patch.)
• Keep the same patch change day.
• No additional contraceptive protection is   
 needed.
• Emergency contraception is not usually   
 needed but can be considered if delayed   
 application or detachment occurred earlier  
 in the cycle or in the last week of the   
 previous cycle.
• Apply a new patch as soon as possible.
• Keep the same patch change day.
• Use back-up contraception (e.g., condoms)  
 or avoid sexual intercourse until a patch has  
 been worn for 7 consecutive days.
• If the delayed application or detachment   
 occurred in the third patch week: 
 — Omit the hormone-free week by   
   finishing the third week of patch use   
   (keeping the same patch change day)  
   and starting a new patch immediately.
 — If unable to start a new patch   
   immediately, use back-up    
   contraception (e.g., condoms) or avoid  
   sexual intercourse until a new patch has  
   been worn for 7 consecutive days.
• Emergency contraception should be   
 considered if the delayed application or   
 detachment occurred within the first week  
 of patch use and unprotected sexual   
 intercourse occurred in the previous 5 days.
• Emergency contraception may also be   
 considered at other times as appropriate.
* If detachment takes place but the woman is unsure when the detachment occurred, consider the patch to have been detached for ≥48 hours since a patch should 
have been applied or reattached.
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combined hormonal contraceptives, information about 
common side effects such as unscheduled spotting or bleeding, 
especially during the first 3–6 months of use, should be 
discussed (248). These bleeding irregularities are generally 
not harmful and usually improve with persistent use of the 
hormonal method. To avoid unscheduled spotting or bleeding, 
counseling should emphasize the importance of correct use and 
timing; for users of contraceptive pills, emphasize consistent 
pill use. Enhanced counseling about expected bleeding patterns 
and reassurance that bleeding irregularities are generally not 
harmful has been shown to reduce method discontinuation in 
clinical trials with DMPA (101,102).
A systematic review identified three studies with small study 
populations that addressed treatments for unscheduled bleeding 
among women using extended or continuous combined 
hormonal contraceptives (25). In two separate randomized 
clinical trials in which women were taking either contraceptive 
pills or using the contraceptive ring continuously for 168 days, 
women assigned to a hormone-free interval of 3 or 4 days 
reported improved bleeding. Although they noted an initial 
increase in flow, this was followed by an abrupt decrease 7–8 
days later with eventual cessation of flow 11–12 days later. 
These findings were compared with women who continued to 
use their method without a hormone-free interval, in which a 
greater proportion reported either treatment failure or fewer 
days of amenorrhea (249,250). In another randomized trial of 
66 women with unscheduled bleeding among women using 84 
days of hormonally active contraceptive pills, oral doxycycline 
(100 mg twice daily) initiated the first day of bleeding and 
taken for 5 days did not result in any improvement in bleeding 
compared with placebo (251) (Level of evidence: I, fair, direct).
Progestin-Only Pills
POPs contain only a progestin and no estrogen and are 
available in the United States. Approximately 9 out of 100 
women become pregnant in the first year of use with POPs 
with typical use (59). POPs are reversible and can be used 
by women of all ages. POPs do not protect against STDs; 
consistent and correct use of male latex condoms reduces the 
risk for STDs, including HIV.
FIGURE 4. Recommended actions after delayed insertion or reinsertion with combined vaginal ring
Delayed insertion of a new ring or delayed 
reinsertion* of a current ring for  <48 hours 
since a ring should have been inserted
Delayed insertion of a new ring or delayed 
reinsertion* for ≥48 hours since a ring should 
have been inserted
• Insert ring as soon as possible.
• Keep the ring in until the scheduled ring   
 removal day.
• No additional contraceptive protection is   
 needed.
• Emergency contraception is not usually   
 needed but can be considered if delayed   
 insertion or reinsertion occurred earlier in  
 the cycle or in the last week of the previous  
 cycle.
• Insert ring as soon as possible.
• Keep the ring in until the scheduled ring   
 removal day.
• Use back-up contraception (e.g., condoms)  
 or avoid sexual intercourse until a ring has  
 been worn for 7 consecutive days.
• If the ring removal occurred in the third   
 week of ring use: 
 — Omit the hormone-free week by   
   nishing the third week of ring use and  
   starting a new ring immediately.
 — If unable to start a new ring   
   immediately, use back-up contraception  
   (e.g., condoms) or avoid sexual   
   intercourse until a new ring has been   
   worn for 7 consecutive days.
• Emergency contraception should be   
 considered if the delayed insertion or   
 reinsertion occurred within the rst week of  
 ring use and unprotected sexual intercourse  
 occurred in the previous 5 days.
• Emergency contraception may also be   
 considered at other times as appropriate.
* If removal takes place but the woman is unsure of how long the ring has been removed, consider the ring to have been removed for ≥48 hours since a ring should 
have been inserted or reinserted.
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that the woman is not pregnant (Box 1).
Need for Back-Up Contraception
•	 If	POPs	are	started	within	the	first	5	days	since	menstrual	
bleeding started, no additional contraceptive protection 
is needed.
•	 If	POPs	are	started	>5	days	since	menstrual	bleeding	started,	
the woman needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 2 days.
Special Considerations
Amenorrhea (Not Postpartum)
•	Timing: POPs can be started at any time if it is reasonably 
certain that the woman is not pregnant (Box 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 2 days.
Postpartum (Breastfeeding)
•	 Timing: POPs can be started at any time, including 
immediately postpartum (U.S. MEC 2 if <1 month postpartum 
and U.S. MEC 1 if ≥1 month postpartum) if it is reasonably 
certain that the woman is not pregnant (Box 1).
•	Need for back-up contraception: If the woman is 
<6 months postpartum, amenorrheic, and fully or nearly 
fully breastfeeding (exclusively breastfeeding or the vast 
majority [≥85%] of feeds are breastfeeds) (60), no 
additional contraceptive protection is needed. Otherwise, 
a woman who is ≥21 days postpartum and has not 
experienced return of her menstrual cycles needs to abstain 
from sexual intercourse or use additional contraceptive 
protection for the next 2 days. If her menstrual cycles have 
FIGURE 5. Recommended steps after vomiting or diarrhea while using combined oral contraceptives
Vomiting or diarrhea (for any 
reason, for any duration) that 
occurs within 24 hours after 
taking a hormonal pill
Vomiting or diarrhea, for any 
reason, continuing for 24 to <48 
hours after taking any hormonal 
pill
Vomiting or diarrhea, for any reason, 
continuing for ≥48 hours after taking any 
hormonal pill
• Taking another hormonal pill   
 (redose) is unnecessary.
• Continue taking pills daily at the  
 usual time (if possible, despite   
 discomfort).
• No additional contraceptive   
 protection is needed.
• Emergency contraception is not  
 usually needed but can be   
 considered as appropriate.
• Continue taking pills daily at the usual  
 time (if possible, despite discomfort).
• Use back-up contraception (e.g.,  
 condoms) or avoid sexual intercourse  
 until hormonal pills have been taken  
 for 7 consecutive days after vomiting or  
 diarrhea has resolved.
• If vomiting or diarrhea occurred in the  
 last week of hormonal pills (e.g., days  
 15–21 for 28-day pill packs):
 — Omit the hormone-free interval by  
   nishing the hormonal pills in the  
   current pack and starting a new  
   pack the next day.
 — If unable to start a new pack  
   immediately, use back-up   
   contraception (e.g., condoms) or  
   avoid sexual intercourse until  
   hormonal pills from a new pack  
   have been taken for 7 consecutive  
   days.
• Emergency contraception should be  
 considered if vomiting or diarrhea  
 occurred within the rst week of a new  
 pill pack and unprotected sexual   
 intercourse occurred in the previous 5  
 days.
• Emergency contraception may also be  
 considered at other times as   
 appropriate.
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returned and it has been >5 days since menstrual bleeding 
started, she needs to abstain from sexual intercourse or use 
additional contraceptive protection for the next 2 days.
Postpartum (Not Breastfeeding)
•	Timing: POPs can be started at any time, including 
immediately postpartum (U.S. MEC 1), if it is reasonably 
certain that the woman is not pregnant (Box 1).
•	Need for back-up contraception: Women who are 
≥21 days postpartum and whose menstrual cycles have 
not returned need to abstain from sexual intercourse or 
use additional contraceptive protection for the next 2 days. 
If her menstrual cycles have returned and it has been >5 
days since menstrual bleeding started, she needs to abstain 
from sexual intercourse or use additional contraceptive 
protection for the next 2 days.
Postabortion (Spontaneous or Induced)
•	Timing: POPs can be started within the first 7 days, 
including immediately postabortion (U.S. MEC 1).
•	Need for back-up contraception: The woman needs to 
abstain from sexual intercourse or use additional 
contraceptive protection for the next 2 days unless POPs 
are started at the time of a surgical abortion.
Switching from Another Contraceptive Method
•	Timing: POPs can be started immediately if it is reasonably 
certain that the woman is not pregnant (Box 1). Waiting 
for her next menstrual period is unnecessary.
•	Need for back-up contraception: If it has been >5 days 
since menstrual bleeding started, she needs to abstain from 
sexual intercourse or use additional contraceptive 
protection for the next 2 days.
•	 Switching from an IUD: If the woman has had sexual 
intercourse since the start of her current menstrual cycle and 
it has been >5 days since menstrual bleeding started, 
theoretically, residual sperm might be in the genital tract, 
which could lead to fertilization if ovulation occurs. A health-
care provider may consider any of the following options:
 – Advise the women to retain the IUD for at least 2 days 
after POPs are initiated and return for IUD removal.
 – Advise the woman to abstain from sexual intercourse 
or use barrier contraception for 2 days before removing 
the IUD and switching to the new method.
 – Advise the woman to use ECPs at the time of IUD removal.
Comments and Evidence Summary. In situations in which 
the health-care provider is uncertain whether the woman might 
be pregnant, the benefits of starting POPs likely exceed any 
risk; therefore, starting POPs should be considered at any time, 
with a follow-up pregnancy test in 2–4 weeks.
Unlike COCs, POPs inhibit ovulation in about half of cycles, 
although the rates vary widely by individual (252). Peak serum 
steroid levels are reached about 2 hours after administration, 
followed by rapid distribution and elimination, such that by 
24 hours after administration, serum steroid levels are near 
baseline (252). Therefore, taking POPs at approximately 
the same time each day is important. An estimated 48 
hours of POP use has been deemed necessary to achieve the 
contraceptive effects on cervical mucus (252). If a woman needs 
to use additional contraceptive protection when switching to 
POPs from another contraceptive method, consider continuing 
her previous method for 2 days after starting POPs. No direct 
evidence was found regarding the effects of starting POPs at 
different times of the cycle.
Examinations and Tests Needed Before 
Initiation of POPs
Among healthy women, no examinations or tests are needed 
before initiation of POPs, although a baseline weight and BMI 
measurement might be useful for monitoring POP users over 
time (Table 6). Women with known medical problems or 
other special conditions might need additional examinations 
or tests before being determined to be appropriate candidates 
TABLE 6. Classification of examinations and tests needed before POP 
initiation
Examination or laboratory test Class*
Examination
Blood pressure C
Weight (BMI) (weight [kg]/height [m]2) —†
Clinical breast examination C







Cervical cytology (Papanicolaou smear) C
STD screening with laboratory tests C
HIV screening with laboratory tests C
Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; 
POP = progestin-only pill; STD = sexually transmitted disease; U.S. MEC = U.S. 
Medical Eligibility Criteria for Contraceptive Use, 2010.
* Class A: essential and mandatory in all circumstances for safe and effective 
use of the contraceptive method. Class B: contributes substantially to safe and 
effective use, but implementation may be considered within the public health 
and/or service context; the risk of not performing an examination or test should 
be balanced against the benefits of making the contraceptive method 
available. Class C: does not contribute substantially to safe and effective use 
of the contraceptive method.
† Weight (BMI) measurement is not needed to determine medical eligibility for 
any methods of contraception because all methods can be used (U.S. MEC 1) or 
generally can be used (U.S. MEC 2) among obese women (Box 2). However, 
measuring weight and calculating BMI at baseline might be helpful for 
monitoring any changes and counseling women who might be concerned about 
weight change perceived to be associated with their contraceptive method. 
Recommendations and Reports
32 MMWR / June 21, 2013 / Vol. 62 / No. 5
for a particular method of contraception. U.S. MEC might 
be useful in such circumstances (5).
Comments and Evidence Summary. Weight (BMI): Obese 
women can use POPs (U.S. MEC 1) (5); therefore, screening 
for obesity is not necessary for the safe initiation of POPs. 
However, measuring weight and calculating BMI at baseline 
might be helpful for monitoring any changes and counseling 
women who might be concerned about weight change 
perceived to be associated with their contraceptive method.
Bimanual examination and cervical inspection: Pelvic 
examination is not necessary before initiation of POPs because 
it does not facilitate detection of conditions for which POPs 
would be unsafe. Women with current breast cancer should 
not use POPs (U.S. MEC 4), and women with certain liver 
diseases generally should not use POPs (U.S. MEC 3) (5); 
however, neither of these conditions are likely to be detected 
by pelvic examination (120). A systematic review identified 
two case-control studies that compared delayed versus 
immediate pelvic examination before initiation of hormonal 
contraceptives, specifically oral contraceptives or DMPA (15). 
No differences in risk factors for cervical neoplasia, incidence 
of STDs, incidence of abnormal Papanicolaou smears, or 
incidence of abnormal wet mounts were observed (Level of 
evidence: II-2 fair, direct).
Liver enzymes: Although women with certain liver diseases 
generally should not use POPs (U.S. MEC 3) (5), screening 
for liver disease before initiation of POPs is not necessary 
because of the low prevalence of these conditions and the 
high likelihood that women with liver disease already would 
have had the condition diagnosed. A systematic review did 
not identify any evidence regarding outcomes among women 
who were screened versus not screened with liver enzyme 
tests before initiation of hormonal contraceptives (14). The 
prevalence of liver disorders among women of reproductive 
age is low. In 2008 among U.S. adults aged 18–44 years, 
the percentage with liver disease (not further specified) was 
1.0% (90). In 2009, the incidence of acute hepatitis A, B, 
or C among women was <1 per 100,000 population (91). 
During 1998–2007, the incidence of liver carcinoma among 
women was approximately 3 per 100,000 population (92). 
Because estrogen and progestins are metabolized in the liver, 
the use of hormonal contraceptives among women with liver 
disease might, theoretically, be a concern. The use of hormonal 
contraceptives, specifically COCs and POPs, does not affect 
disease progression or severity in women with hepatitis, 
cirrhosis, or benign focal nodular hyperplasia (93,94).
Clinical breast examination: Although women with current 
breast cancer should not use POPs (U.S. MEC 4) (5), screening 
asymptomatic women with a clinical breast examination 
before initiating POPs is not necessary because of the low 
prevalence of breast cancer among women of reproductive age. 
A systematic review did not identify any evidence regarding 
outcomes among women who were screened versus not 
screened with a clinical breast examination before initiation of 
hormonal contraceptives (15). The incidence of breast cancer 
among women of reproductive age in the United States is low. 
In 2009, the incidence of breast cancer among women ages 
20–49 was approximately 72 per 100,000 women (95).
Other screening: Women with hypertension, diabetes, 
hyperlipidemia, anemia, thrombogenic mutations, cervical 
intraepithelial neoplasia, cervical cancer, STDs, or HIV 
infection can use (U.S. MEC 1) or generally can use (U.S. 
MEC 2) POPs  (5); therefore, screening for these conditions 
is not necessary for the safe initiation of POPs.
Number of Pill Packs that Should Be 
Provided at Initial and Return Visits
•	 At	the	initial	and	return	visits,	provide	or	prescribe	up	to	a	
1-year supply of POPs (e.g., 13 28-day pill packs), 
depending on the woman’s preferences and anticipated use.
•	 A	woman	 should	be	 able	 to	 obtain	POPs	 easily	 in	 the	
amount and at the time she needs them.
Comments and Evidence Summary. The more pill packs 
given up to 13 cycles, the higher the continuation rates. 
Restricting the number of pill packs distributed or prescribed 
can result in unwanted discontinuation of the method and 
increased risk for pregnancy.
A systematic review of the evidence suggested that providing 
a greater number of pill packs was associated with increased 
continuation (23). Studies that compared provision of one 
versus 12 packs, one versus 12 or 13 packs, or three versus 
seven packs found increased continuation of pill use among 
women provided with more pill packs (209–211). However, 
one study found that there was no difference in continuation 
when patients were provided one and then three packs versus 
four packs all at once (212). In addition to continuation, a 
greater number of pill packs provided was associated with fewer 
pregnancy tests, fewer pregnancies, and lower cost per client. 
However, a greater number of pill packs (13 packs versus three 
packs) also was associated with increased pill wastage in one 
study (210) (Level of evidence: I to II-2, fair, direct).
Routine Follow-Up After POP Initiation
These recommendations address when routine follow-up 
is recommended for safe and effective continued use of 
contraception for healthy women. The recommendations refer 
to general situations and might vary for different users and 
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different situations. Specific populations that might benefit 
from more frequent follow-up visits include adolescents, those 
with certain medical conditions or characteristics, and those 
with multiple medical conditions.
•	 Advise	a	woman	to	return	at	any	time	to	discuss	side	effects	
or other problems or if she wants to change the method 
being used. No routine follow-up visit is required.
•	 At	other	routine	visits,	health-care	providers	seeing	POP	
users should do the following:
 – Assess the woman’s satisfaction with her contraceptive 
method and whether she has any concerns about 
method use.
 – Assess any changes in health status, including medications, 
that would change the appropriateness of  POPs for safe 
and effective continued use based on U.S. MEC (e.g., 
category 3 and 4 conditions and characteristics).
 – Consider assessing weight changes and counseling women 
who are concerned about weight changes perceived to be 
associated with their contraceptive method.
Comments and Evidence Summary. No evidence was 
found regarding whether a routine follow-up visit after 
initiating POPs improves correct or continued use.
Missed POPs
For the following recommendations, a dose is considered 
missed if it has been >3 hours since it should have been taken.
•	 Take	one	pill	as	soon	as	possible.
•	 Continue	taking	pills	daily,	one	each	day,	at	the	same	time	
each day, even if it means taking two pills on the same day.
•	 Use	back-up	contraception	(e.g.,	condoms)	or	avoid	sexual	
intercourse until pills have been taken correctly, on time, 
for 2 consecutive days.
•	 Emergency	 contraception	 should	 be	 considered	 if	 the	
woman has had unprotected sexual intercourse.
Comments and Evidence Summary. Inconsistent or 
incorrect use of oral contraceptive pills is a major reason for oral 
contraceptive failure. Unlike COCs, POPs inhibit ovulation 
in about half of cycles, although this rate varies widely by 
individual (252). Peak serum steroid levels are reached about 
2 hours after administration, followed by rapid distribution 
and elimination, such that by 24 hours after administration, 
serum steroid levels are near baseline (252). Therefore, taking 
POPs at approximately the same time each day is important. 
An estimated 48 hours of POP use was deemed necessary to 
achieve the contraceptive effects on cervical mucus (252). 
Women who frequently miss POPs should consider an 
alternative  contraceptive method that is less dependent on 
the user to be effective  (e.g., IUD, implant, or injectable). 
No evidence was found regarding the effects of missed POPs 
available in the United States on measures of contraceptive 
effectiveness including pregnancy, follicular development, 
hormone levels, or cervical mucus quality.
Vomiting or Severe Diarrhea (for any 
Reason or Duration) that Occurs Within 






intercourse until 2 days after vomiting or diarrhea has resolved.
•	 Emergency	 contraception	 should	 be	 considered	 if	 the	
woman has had unprotected sexual intercourse.
Comments and Evidence Summary. Theoretically, the 
contraceptive effectiveness of POPs might be decreased because 
of vomiting or severe diarrhea.  Because of the lack of evidence 
to address this question, these recommendations are based on 
the recommendations for missed POPs. No evidence was found 
regarding the effects of vomiting or diarrhea on measures of 
contraceptive effectiveness, including pregnancy, follicular 
development, hormone levels, or cervical mucus quality.
Standard Days Method
SDM is a method based on fertility awareness; users must 
avoid unprotected sexual intercourse on days 8–19 of the 
menstrual cycle (253). Approximately 5 out of 100 women 
become pregnant in the first year of use with perfect (i.e., 
correct and consistent) use of SDM (253); effectiveness based 
on typical use is not available for this method but is expected 
to be lower than that for perfect use. SDM is reversible and can 
be used by women of all ages. SDM does not protect against 
STDs; consistent and correct use of male latex condoms reduces 
the risk for STDs, including HIV.
Use of SDM Among Women with Various 
Menstrual Cycle Durations
Menstrual Cycles of 26–32 Days
•	 These	women	may	use	the	method.
•	 Provide	a	barrier	method	of	contraception	for	protection	
on days 8–19 if she wants one.
•	 If	she	has	unprotected	sexual	intercourse	during	days	8–19,	
consider the use of emergency contraception if appropriate.
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Two or More Menstrual Cycles of <26 or >32 Days 
Within Any 1 Year of SDM Use
•	 Advise	 the	 woman	 that	 the	method	might	 not	 be	
appropriate for her because of a higher risk for pregnancy. 
Help her consider another method.
Comments and Evidence Summary. The probability of 
pregnancy is increased when the menstrual cycle is outside the 
range of 26–32 days, even if unprotected sexual intercourse is 
avoided on days 8–19. A study of 7,600 menstrual cycles, including 
information on cycle length and signs of ovulation, concluded that 
the theoretical effectiveness of SDM is greatest for women with 
cycles of 26–32 days, that the method is still effective for women 
who occasionally have a cycle outside this range, and that it is 
less effective for women who consistently have cycles outside this 
range. Information from daily hormonal measurements shows 
that the timing of the 6-day fertile window varies greatly, even 
among women with regular cycles (39,254,255).
Emergency Contraception
Emergency contraception consists of methods that can be 
used by women after sexual intercourse to prevent pregnancy. 
Emergency contraception methods have varying ranges 
of effectiveness depending on the method and timing of 
administration. Four options are available in the United States: 
the Cu-IUD and three types of ECPs.






(1 dose of 0.75 mg of levonorgestrel followed by a second 
dose of 0.75 mg of levonorgestrel 12 hours later)
•	 Combined	estrogen	and	progestin	in	2	doses	(Yuzpe	regimen:	
1 dose of 100 µg of ethinyl estradiol plus 0.50 mg of 
levonorgestrel followed by a second dose of 100 µg of ethinyl 
estradiol plus 0.50 mg of levonorgestrel 12 hours later)




unprotected sexual intercourse as an emergency contraceptive.
•	 In	addition,	when	the	day	of	ovulation	can	be	estimated,	
the Cu-IUD can be inserted beyond 5 days after sexual 





Comments and Evidence Summary. Cu-IUDs are highly 
effective as emergency contraception (256) and can be 
continued as regular contraception. UPA and levonorgestrel 
ECPs have similar effectiveness when taken within 3 days after 
unprotected sexual intercourse; however, UPA has been shown 
to be more effective than the levonorgestrel formulation 3–5 
days after unprotected sexual intercourse (257). The combined 
estrogen and progestin regimen is less effective than UPA 
or levonorgestrel and also is associated with more frequent 
occurrence of side effects (nausea and vomiting) (258). The 
levonorgestrel formulation might be less effective than UPA 
among obese women (257).
Two studies of UPA use found consistent decreases in 
pregnancy rates when administered within 120 hours of 
unprotected sexual intercourse (257,259). Five studies found 
that the levonorgestrel and combined regimens decreased risk 
for pregnancy through the fifth day after unprotected sexual 
intercourse; however, rates of pregnancy were slightly higher 
when ECPs were taken after 3 days (260–264). A meta-analysis 
of levonorgestrel ECPs found that pregnancy rates were low 
when administered within 4 days after unprotected sexual 
intercourse but increased at 4–5 days (265) (Level of evidence: 
I to II-2, good to poor, direct).
Advance Provision of ECPs
•	 An	advance	supply	of	ECPs	may	be	provided	so	that	ECPs	
will be available when needed and can be taken as soon as 
possible after unprotected sexual intercourse.
Comments and Evidence Summary. A systematic review 
identified 17 studies that reported on safety or effectiveness of 
advance ECPs in adult or adolescent women (26). Any use of 
ECPs was two to seven times greater among women who received 
an advance supply of ECPs. However, a summary estimate 
(relative risk = 0.97; 95% confidence interval = 0.77–1.22) of 
five randomized controlled trials did not indicate a significant 
reduction in unintended pregnancies at 12 months with 
advance provision of ECPs. In the majority of studies among 
adults or adolescents, patterns of regular contraceptive use, 
pregnancy rates, and incidence of STDs did not vary between 
those who received advance ECPs and those who did not. 
Although available evidence supports the safety of advance 
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provision of ECPs, effectiveness of advance provision of ECPs 
in reducing pregnancy rates at the population level has not been 
demonstrated (Level of evidence: I to II-3, good to poor, direct).
Initiation of Regular Contraception 
After ECPs
UPA
•	 Any	 regular	 contraceptive	 method	 can	 be	 started	
immediately after the use of UPA.
•	 The	woman	needs	to	abstain	from	sexual	intercourse	or	
use barrier contraception for 14 days or until her next 
menses, whichever comes first.
•	 Advise	the	woman	to	have	a	pregnancy	test	if	she	does	not	
have a withdrawal bleed within 3 weeks.
Levonorgestrel and Combined Estrogen and 
Progestin ECPs
•	 Any	 regular	 contraceptive	 method	 can	 be	 started	
immediately after the use of levonorgestrel or combined 
estrogen and progestin ECPs.
•	 The	woman	needs	to	abstain	from	sexual	intercourse	or	
use barrier contraception for 7 days.
•	 Advise	the	woman	to	have	a	pregnancy	test	if	she	does	not	
have a withdrawal bleed within 3 weeks.
Comments and Evidence Summary. Data on when a 
woman can start regular contraception after ECPs are limited 
to expert opinion and product labeling (27). Theoretically, 
the effectiveness of systemic hormonal contraception might 
be decreased when administered concurrently or in close 
succession because of the antiprogestin properties of UPA 
(266,267); these theoretical concerns do not exist for combined 
estrogen and progestin or levonorgestrel formulations of 
ECPs. The resumption or initiation of regular hormonal 
contraception after ECP use involves consideration of the 
risk for pregnancy if ECPs fail and the risks for unintended 
pregnancy if contraception initiation is delayed until the 
subsequent menstrual cycle. If a woman is planning to initiate 
contraception after the next menstrual period after ECP 
use, the cycle in which ECPs are used might be shortened, 
prolonged, or involve unscheduled bleeding.
Prevention and Management of Nausea 
and Vomiting with ECP Use
Nausea and Vomiting
•	 Levonorgestrel	 and	UPA	ECPs	 cause	 less	 nausea	 and	
vomiting than combined estrogen and progestin ECPs.
•	 Routine	 use	 of	 antiemetics	 before	 taking	ECPs	 is	 not	
recommended. Pretreatment with antiemetics may be 
considered depending on availability and clinical judgment.
Vomiting Within 3 Hours of Taking ECPs
•	 Another	dose	of	ECP	should	be	taken	as	soon	as	possible.	
Use of an antiemetic should be considered.
Comments and Evidence Summary. Many women do 
not experience nausea or vomiting when taking ECPs, and 
predicting which women will experience nausea or vomiting 
is difficult. Although routine use of antiemetics before taking 
ECPs is not recommended, antiemetics are effective in some 
women and can be offered when appropriate. Health-care 
providers who are deciding whether to offer antiemetics to 
women taking ECPs should consider the following: 1) women 
taking combined estrogen and progestin ECPs are more 
likely to experience nausea and vomiting than those who 
take levonorgestrel or UPA ECPs; 2) evidence indicates that 
antiemetics reduce the occurrence of nausea and vomiting in 
women taking combined estrogen and progestin ECPs; and 
3) women who take antiemetics might experience other side 
effects from the antiemetics.
A systematic review examined incidence of nausea and 
vomiting with different ECP regimens and effectiveness of 
antinausea drugs in reducing nausea and vomiting with ECP 
use (28). The levonorgestrel regimen was associated with 
significantly less nausea than a nonstandard dose of UPA 
(50 mg) and the standard combined estrogen and progestin 
regimen (268–270). Use of the split-dose levonorgestrel 
showed no differences in nausea and vomiting compared 
with the single-dose levonorgestrel (260,261,263,271) (Level 
of evidence: I, good-fair, indirect). Two trials of antinausea 
drugs, meclizine and metoclopramide, taken before combined 
estrogen and progestin ECPs, reduced the severity of nausea 
(272,273). Significantly less vomiting occurred with meclizine 
but not metoclopramide (Level of evidence: I, good-fair, 
direct). No direct evidence was found regarding the effects of 
vomiting after taking ECPs.
Female Sterilization 
Laparoscopic, abdominal, and hysteroscopic methods of 
female sterilization are available in the United States, and 
some of these procedures can be performed in an outpatient 
procedure or office setting. Fewer than 1 out of 100 women 
become pregnant in the first year after female sterilization 
(59). Because these methods are intended to be irreversible, 
all women should be appropriately counseled about the 
permanency of sterilization and the availability of highly 
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effective, long-acting, reversible methods of contraception. 
Female sterilization does not protect against STDs; consistent 
and correct use of male latex condoms reduces the risk for 
STDs, including HIV.
When Hysteroscopic Sterilization Is 
Reliable for Contraception
•	 Before	a	woman	can	rely	on	hysteroscopic	sterilization	for	
contraception, a hysterosalpingogram (HSG) must be 
performed 3 months after the sterilization procedure to 
confirm bilateral tubal occlusion. 
•	 The	woman	should	be	advised	that	she	needs	to	abstain	
from sexual intercourse or use additional contraceptive 
protection until she has confirmed bilateral tubal occlusion.
When Laparoscopic and Abdominal 
Approches Are Reliable for Contraception
•	 A	woman	 can	 rely	 on	 sterilization	 for	 contraception	
immediately after laparoscopic and abdominal approaches. 
No additional contraceptive protection is needed.
Comments and Evidence Summary. HSG confirmation 
is necessary to confirm bilateral tubal occlusion after 
hysteroscopic sterilization. The inserts for the hysteroscopic 
sterilization system available in the United States are placed 
bilaterally into the fallopian tubes and require 3 months 
for adequate fibrosis and scarring leading to bilateral tubal 
occlusion. After hysteroscopic sterilization, advise the woman 
to correctly and consistently use an effective method of 
contraception while awaiting confirmation. If compliance 
with another method might be a problem, a woman and her 
health-care provider may consider DMPA injection at the time 
of sterilization to ensure adequate contraception for 3 months. 
Unlike laparoscopic and abdominal sterilizations, pregnancy 
risk beyond 7 years of follow-up has not been studied among 
women who received  hysteroscopic sterilization.
Pregnancy risk with at least 10 years of follow-up has 
been studied among women who received laparoscopic and 
abdominal sterilizations (274,275). Although these methods 
are highly effective, pregnancies can occur many years after 
the procedure, and the risk for pregnancy is higher among 
younger women (274,276).
A systematic review was conducted to identify studies that 
reported whether pregnancies occurred after hysteroscopic 
sterilization (29). Twenty-four studies were identified that 
reported whether pregnancies occurred after hysteroscopic 
sterilization and found that very few pregnancies occurred 
among women with confirmed bilateral tubal occlusion; 
however, few studies include long-term follow-up, and 
none with follow-up for >7 years. Among women who had 
successful bilateral placement, most pregnancies that occurred 
after hysteroscopic sterilization were in women who did 
not have confirmed bilateral tubal occlusion at 3 months, 
either because of lack of follow up or misinterpretation of 
HSG results (277–279). Some pregnancies occurred within 
3 months of placement, including among women who were 
already pregnant at the time of the procedure, women who 
did not use alternative contraception, or women who had 
failures of alternative contraception (277,278,280–283). 
Although these studies generally demonstrated high rates of 
bilateral placement, some pregnancies occurred as a result 
of lack of bilateral placement identified on later imaging 
(277,278,280,281,283,284). Most pregnancies occurred after 
deviations from FDA directions, which include placement in 
the early follicular phase of the menstrual cycle, imaging at 
3 months to document proper placement, and use of effective 
alternative contraception until documented occlusion (Level 
of evidence: II-3, fair, direct).
Male Sterilization 
Male sterilization, or vasectomy, is one of the few 
contraceptive methods available to men and can be performed 
in an outpatient procedure or office setting. Fewer than 1 
woman out of 100 becomes pregnant in the first year after 
her male partner undergoes sterilization (59). Because male 
sterilization is intended to be irreversible, all men should be 
appropriately counseled about the permanency of sterilization 
and the availability of highly effective, long-acting, reversible 
methods of contraception for women. Male sterilization does 
not protect against STDs; consistent and correct use of male 
latex condoms reduces the risk for STDs, including HIV.
When Vasectomy Is Reliable for 
Contraception
•	 A	semen	analysis	should	be	performed	8–16	weeks	after	
a vasectomy to ensure the procedure was successful.
•	 The	man	should	be	advised	that	he	should	use	additional	
contraceptive protection or abstain from sexual intercourse 




1 week after the vasectomy to allow for healing of surgical 
sites and, after certain methods of vasectomy, occlusion 
of the vas.
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Comments and Evidence Summary. The Vasectomy 
Guideline Panel of the American Urological Association 
performed a systematic review of key issues concerning the 
practice of vasectomy (285). All English-language publications 
on vasectomy published during 1949–2011 were reviewed. For 
more information, see the American Urological Association 
Vasectomy Guidelines (available at http://www.auanet.org/
education/vasectomy.cfm).
Motile sperm disappear within a few weeks after vasectomy 
(286–289). The time to azoospermia varies widely in different 
studies; however, by 12 weeks after the vasectomy, 80% of men 
have azoospermia, and almost all others have rare nonmotile 
sperm (defined as ≤100,000 nonmotile sperm per milliliter) 
(285). The number of ejaculations after vasectomy is not a 
reliable indicator of when azoospermia or rare nonmotile sperm 
will be achieved (285). Once azoospermia or rare nonmotile 
sperm has been achieved, patients can rely on the vasectomy for 
contraception, although not with 100% certainty. The risk for 
pregnancy after a man has achieved postvasectomy azoospermia 
is approximately one in 2,000 (290–294).
A median of 78% (range 33%–100%) of men return for 
a single postvasectomy semen analysis (285). In the largest 
cohorts that appear typical of North American vasectomy 
practice, approximately two thirds of men (55%–71%) return 
for at least one postvasectomy semen analysis (291,295–299). 
Assigning men an appointment after their vasectomy might 
improve compliance with follow-up (300).
When Women Can Stop Using 
Contraceptives
•	 Contraceptive	protection	is	still	needed	for	women	aged	
>44 years if the woman wants to avoid pregnancy.
Comments and Evidence Summary. The age at which 
a woman is no longer at risk for pregnancy is not known. 
Although uncommon, spontaneous pregnancies occur 
among women aged >44 years. Both the American College 
of Obstetricians and Gynecologists and the North American 
Menopause Society recommend that women continue 
contraceptive use until menopause or age 50–55 years 
(301,302). The median age of menopause is approximately 51 
years in North America (301) but can vary from ages 40 to 60 
years (303). The median age of definitive loss of natural fertility 
is 41 years but can range up to age 51 years (304,305). No 
reliable laboratory tests are available to confirm definitive loss 
of fertility in a woman. The assessment of follicle-stimulating 
hormone levels to determine when a woman is no longer fertile 
might not be accurate (301).
Health-care providers should consider the risks for becoming 
pregnant in a woman of advanced reproductive age, as well as any 
risks of continuing contraception until menopause. Pregnancies 
among women of advanced reproductive age are at higher 
risk for maternal complications, such as hemorrhage, venous 
thromboembolism, and death, and fetal complications, such 
as spontaneous abortion, stillbirth, and congenital anomalies 
(306–308). Risks associated with continuing contraception, 
in particular risks for acute cardiovascular events (venous 
thromboembolism, myocardial infarction, or stroke) or breast 
cancer, also are important to consider. U.S. MEC states that 
on the basis of age alone, women aged >45 years can use POPs, 
implants, the LNG-IUD, or the Cu-IUD (U.S. MEC 1) (5). 
Women aged >45 years generally can use combined hormonal 
contraceptives and DMPA (U.S. MEC 2) (5). However, women 
in this age group might have chronic conditions or other risk 
factors that might render use of hormonal contraceptive methods 
unsafe; U.S. MEC might be helpful in guiding the safe use of 
contraceptives in these women.
The incidence of venous thromboembolism was higher 
among oral contraceptive users aged ≥45 years compared with 
younger oral contraceptive users in two studies (309–311); 
however, an interaction between hormonal contraception 
and increased age compared with baseline risk was not 
demonstrated (309,310) or was not examined (311). The 
relative risk for myocardial infarction was higher among all 
oral contraceptive users than in nonusers, although a trend of 
increased relative risk with increasing age was not demonstrated 
(312,313). No studies were found regarding the risk for stroke 
in COC users aged ≥45 years (Level of evidence: II-2, good 
to poor, direct).
A pooled analysis by the Collaborative Group on Hormonal 
Factors and Breast Cancer in 1996 (314) found small increased 
relative risks for breast cancer among women aged ≥45 years 
whose last use of combined hormonal contraceptives was <5 
years previously and for those whose last use was 5–9 years 
previously. Seven more recent studies suggested small but 
nonsignificant increased relative risks for breast carcinoma 
in situ or breast cancer among women who had used oral 
contraceptives or DMPA when they were aged ≥40 years 
compared with those who had never used either method 
(315–321) (Level of evidence: II-2, fair, direct).
Conclusion
Women, men, and couples have increasing numbers of safe 
and effective choices for contraceptive methods, including LARC 
methods such as IUDs and implants, to reduce the risk for 
unintended pregnancy. However, with these expanded options 
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comes the need for evidence-based guidance to help health-care 
providers offer quality family planning care to their patients, 
including choosing the most appropriate contraceptive method 
for individual circumstances and using that method correctly, 
consistently, and continuously to maximize effectiveness. 
Removing unnecessary barriers can help patients access and 
successfully use contraceptive methods. Several medical barriers 
to initiating and continuing contraceptive methods might exist, 
such as unnecessary screening examinations and tests before 
starting the method (e.g., a pelvic examination before initiation 
of COCs), inability to receive the contraceptive on the same 
day as the visit (e.g., waiting for test results that might not be 
needed or waiting until the woman’s next menstrual period to 
start use), and difficulty obtaining continued contraceptive 
supplies (e.g., restrictions on number of pill packs dispensed 
at one time). Removing unnecessary steps, such as providing 
prophylactic antibiotics at the time of IUD insertion or requiring 
unnecessary follow-up procedures, also can help patients access 
and successfully use contraception.
Most women can start most contraceptive methods at 
any time, and few examinations or tests, if any, are needed 
before starting a contraceptive method. Routine follow-up 
for most women includes assessment of her satisfaction with 
the contraceptive method, concerns about method use, and 
changes in health status or medications that could affect 
medical eligibility for continued use of the method. Because 
changes in bleeding patterns are one of the major reasons 
for discontinuation of contraception, recommendations are 
provided for the management of bleeding irregularities with 
various contraceptive methods. In addition, because women 
and health-care providers can be confused about the procedures 
for missed pills and dosing errors with the contraceptive patch 
and ring, the instructions are streamlined for easier use. ECPs 
and emergency use of the Cu-IUD are important options for 
women, and recommendations on using these methods, as 
well as starting regular contraception after use of emergency 
contraception, are provided. Male and female sterilization are 
highly effective methods of contraception for men, women, and 
couples who have completed childbearing; for men undergoing 
vasectomy and women undergoing a hysteroscopic sterilization 
procedure, additional contraceptive protection is needed until 
the success of the procedure can be confirmed.
CDC is committed to working with partners at the federal, 
national, and local levels to disseminate, implement, and 
evaluate the recommendations in U.S. SPR so that the 
information reaches health-care providers. Strategies for 
dissemination and implementation include collaborating 
with other federal agencies and professional and service 
organizations to widely distribute the recommendations 
through presentations, electronic distribution, newsletters, and 
other publications; development of provider tools and job aids 
to assist providers in implementing the new recommendations; 
and training activities for students, as well as for continuing 
education. CDC will conduct a survey of family planning 
health-care providers before and after release of this report 
to assess attitudes and practices related to contraceptive 
use. Results from this survey will assist CDC in evaluating 
the impact of these recommendations on the provision 
of contraceptives in the United States. Finally, CDC will 
continually monitor new scientific evidence and will update 
these recommendations as warranted by new evidence. Updates 
to the recommendations, as well as provider tools and other 




This report is based, in part, on the work of the Promoting Family 
Planning Team, Department of Reproductive Health and Research, 
World Health Organization, and its development of the Selected 
Practice Recommendations for Contraceptive Use.
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Appendix A
Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
Updated June 2012.  This summary sheet only contains 
a subset of the recommendations from the US MEC.  
For complete guidance, see: http://www.cdc.gov/
reproductivehealth/unintendedpregnancy/USMEC.htm.
Most contraceptive methods do not protect against sexually 
transmitted infections (STIs).  Consistent and correct use of 
the male latex condom reduces the risk of STIs and HIV.
Key:
1. No restriction (method can be used)
2. Advantages generally outweigh theoretical or proven 
risks
3. Theoretical or proven risks usually outweigh the 
advantages






only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C






















Anemias a) Thalassemia 1 1 1 1 1 2
b) Sickle cell disease† 2 1 1 1 1 2
c) Iron-deficiency 
anemia
1 1 1 1 1 2
Benign ovarian tumors (including cysts) 1 1 1 1 1 1
Breast disease a) Undiagnosed mass 2* 2* 2* 2* 2 1
b) Benign breast 
disease
1 1 1 1 1 1
c) Family history of 
cancer
1 1 1 1 1 1
d) Breast cancer†
     i) current 4 4 4 4 4 1
ii) past and no 
evidence of 
current disease for 
5 years
3 3 3 3 3 1
Breastfeeding  
(see also Postpartum)
a) < 1 month 
postpartum
3* 2* 2* 2*
b) 1 month or more 
postpartum
2* 1* 1* 1*
Cervical cancer Awaiting treatment 2 1 2 2 4 2 4 2




2 1 2 2 2 1
See table footnotes on page 54.
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only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C
Cirrhosis a) Mild 
(compensated)
1 1 1 1 1 1
b) Severe† 
(decompensated)
4 3 3 3 3 1




i) higher risk for 
recurrent DVT/PE 
4 2 2 2 2 1
ii) lower risk for 
recurrent DVT/PE 
3 2 2 2 2 1
b) Acute DVT/PE 4 2 2 2 2 2
c) DVT/PE and 
established on 
anticoagulant 
therapy for at least 3 
months
i) higher risk for 
recurrent DVT/PE 
4* 2 2 2 2 2
ii) lower risk for 
recurrent DVT/PE 
3* 2 2 2 2 2
d) Family history 
(first-degree relatives)
2 1 1 1 1 1
e) Major surgery
(i) with prolonged 
immobilization




2 1 1 1 1 1
f ) Minor 
surgery without 
immobilization
1 1 1 1 1 1
Depressive disorders 1* 1* 1* 1* 1* 1*
See table footnotes on page 54.
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only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C
Diabetes mellitus a) History of 
gestational diabetes 
mellitus only





2 2 2 2 2 1
(ii) insulin 
dependent†




3/4* 2 3 2 2 1
d) Other vascular 
disease or diabetes of 
>20 years’ duration†
3/4* 2 3 2 2 1
Endometrial cancer† 1 1 1 1 4 2 4 2
Endometrial  
hyperplasia
1 1 1 1 1 1
Endometriosis 1 1 1 1 1 2
Epilepsy† (see also Drug 
Interactions)
1* 1* 1* 1* 1 1
Gallbladder disease a) Symptomatic
(i) treated by      
cholecystectomy
2 2 2 2 2 1
     (ii) medically 
treated
3 2 2 2 2 1
(iii) current 3 2 2 2 2 1
b) Asymptomatic 2 2 2 2 2 1
Gestational  
trophoblastic disease
a) Decreasing or 
undetectable ß-hCG 
levels
1 1 1 1 3 3
b) Persistently 
elevated ß-hCG 
levels or malignant 
disease†
1 1 1 1 4 4
Headaches a) Non-migrainous 1* 2* 1* 1* 1* 1* 1* 1* 1* 1* 1*
b) Migraine
i) without aura, 
age <35
2* 3* 1* 2* 2* 2* 2* 2* 2* 2* 1*
ii) without aura, 
age >35
3* 4* 1* 2* 2* 2* 2* 2* 2* 2* 1*
iii) with aura, any 
age
4* 4* 2* 3* 2* 3* 2* 3* 2* 3* 1*
See table footnotes on page 54.
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only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C
History of bariatric surgery† a) Restrictive 
procedures
1 1 1 1 1 1
b) Malabsorptive 
procedures
COCs: 3 3 1 1 1 1
P/R: 1
History of cholestasis a) Pregnancy-related 2 1 1 1 1 1
b) Past COC-related 3 2 2 2 2 1
History of high blood pressure  
during pregnancy 
2 1 1 1 1 1
History of pelvic surgery 1 1 1 1 1 1
HIV High risk 1 1 1* 1 2 2 2 2
HIV infected 
(see also Drug 
Interactions)†
1* 1* 1* 1* 2 2 2 2
AIDS (see also Drug 
Interactions) †
1* 1* 1* 1* 3 2* 3 2*
Clinically well on 
therapy
If on treatment, see Drug Interactions 2 2 2 2
Hyperlipidemias 2/3* 2* 2* 2* 2* 1*
Hypertension a) Adequately 
controlled 
hypertension
3* 1* 2* 1* 1 1





159 or diastolic 
90-99
3 1 2 1 1 1
(ii) systolic ≥160 
or diastolic ≥100†
4 2 3 2 2 1
c) Vascular disease 4 2 3 2 2 1
Inflammatory bowel disease (Ulcerative colitis, 
Crohn’s disease)
2/3* 2 2 1 1 1
Ischemic heart  
disease†
Current and  
history of
4 2 3 3 2 3 2 3 1
Liver tumors a) Benign
i) Focal nodular 
hyperplasia
2 2 2 2 2 1
ii) Hepatocellular 
adenoma†
4 3 3 3 3 1
b) Malignant† 4 3 3 3 3 1
Malaria 1 1 1 1 1 1
See table footnotes on page 54.
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only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C
Multiple risk factors for arterial 
cardiovascular disease
(such as older age, 
smoking, diabetes 
and hypertension)
3/4* 2* 3* 2* 2 1
Obesity a) >30 kg/m2 BMI 2 1 1 1 1 1
b) Menarche to 
<18 years and 
>30 kg/m2  BMI
2 1 2 1 1 1
Ovarian cancer† 1 1 1 1 1 1
Parity a) Nulliparous 1 1 1 1 2 2
b) Parous 1 1 1 1 1 1
Past ectopic  
pregnancy
1 2 1 1 1 1
Pelvic inflammatory disease a) Past, (assuming no 









1 1 1 1 2 2 2 2
b) Current 1 1 1 1 4 2* 4 2*
Peripartum cardiomyopathy† a) Normal or mildly 
impaired cardiac 
function
(i) <6 months 4 1 1 1 2 2
(ii) >6 months 3 1 1 1 2 2
b) Moderately or 
severely impaired 
cardiac function
4 2 2 2 2 2
Postabortion a) First trimester 1* 1* 1* 1* 1* 1*
b) Second trimester 1* 1* 1* 1* 2 2
c) Immediately post-
septic abortion
1* 1* 1* 1* 4 4
Postpartum  
(see also Breastfeeding)
a)  <21 days 4 1 1 1
b)  21 days to 
42 days 
(i) with other risk 
factors for VTE 3* 1 1 1
(ii) without other 
risk factors for 
VTE
2 1 1 1
c)  >42 days 1 1 1 1
See table footnotes on page 54.
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only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C
Postpartum (in breastfeeding 
or non-breastfeeding women, 
including post-cesarean 
section)
a) <10 minutes after 
delivery of the 
placenta
2 1
b) 10 minutes after 




c) >4 weeks 1 1
d) Puerperal sepsis 4 4






2 1 2/3* 1 2 1 2 1
b) Not on 
immunosuppressive 
therapy
2 1 2 1 1 1
Schistosomiasis a) Uncomplicated 1 1 1 1 1 1
b) Fibrosis of the 
liver†
1 1 1 1 1 1
Severe dysmenorrhea 1 1 1 1 1 2




1 1 1 1 4 2* 4 2*
b) Other STIs 
(excluding HIV and 
hepatitis)






1 1 1 1 2 2 2 2
d) Increased risk of 
STIs
1 1 1 1 2/3* 2 2/3* 2
Smoking a) Age <35 2 1 1 1 1 1
b) Age >35, <15 
cigarettes/day
3 1 1 1 1 1
c) Age >35, >15 
cigarettes/day
4 1 1 1 1 1
Solid organ  
transplantation†
a) Complicated 4 2 2 2 3 2 3 2
b) Uncomplicated 2* 2 2 2 2 2
Stroke† History of 
cerebrovascular 
accident
4 2 3 3 2 3 2 1
See table footnotes on page 54.
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only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C
Superficial venous thrombosis a) Varicose veins 1 1 1 1 1 1
b) Superficial 
thrombophlebitis
2 1 1 1 1 1
Systemic lupus  
erythematosus†




4 3 3 3 3 3 1 1
b) Severe 
thrombocytopenia




2 2 2 2 2 2 2 1
d) None of the above 2 2 2 2 2 2 1 1
Thrombogenic  
mutations†
4* 2* 2* 2* 2* 1*
Thyroid disorders Simple goiter/ 
hyperthyroid/
hypothyroid
1 1 1 1 1 1
Tuberculosis†  
(see also Drug  
Interactions)
a) Non-pelvic 1* 1* 1* 1* 1 1
b) Pelvic 1* 1* 1* 1* 4 3 4 3
Unexplained vaginal bleeding (suspicious for 
serious condition) 
before evaluation
2* 2* 3* 3* 4* 2* 4* 2*
Uterine fibroids 1 1 1 1 2 2
Valvular heart  
disease
a) Uncomplicated 2 1 1 1 1 1
b) Complicated† 4 1 1 1 1 1
Vaginal bleeding  
patterns
a) Irregular pattern 
without heavy 
bleeding
1 2 2 2 1 1 1
b) Heavy or 
prolonged bleeding
1* 2* 2* 2* 1* 2* 2*
Viral hepatitis a) Acute or flare 3/4* 2 1 1 1 1 1
b) Carrier/Chronic 1 1 1 1 1 1 1
See table footnotes on page 54.
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only pill Injection Implant LNG-IUD Copper-IUD
I C I C I C I C I C I C
Drug Interactions
Antiretroviral therapy a) Nucleoside 
reverse transcriptase 
inhibitors




2* 2* 1 2* 2/3* 2* 2/3* 2*
c) Ritonavir-boosted 
protease inhibitors 
3* 3* 1 2* 2/3* 2* 2/3* 2*








3* 3* 1 2* 1 1
b) Lamotrigine 3* 1 1 1 1 1
Antimicrobial therapy a)  Broad spectrum 
antibiotics
1 1 1 1 1 1
b) Antifungals 1 1 1 1 1 1
c) Antiparasitics 1 1 1 1 1 1
d) Rifampicin or 
rifabutin therapy
3* 3* 1 2* 1 1
Abbreviations: AIDS = acquired immunodeficiency syndrome; BMI = body mass index; C = continuation of contraceptive method; COC = combined oral 
contraceptive; Cu-IUD = copper-containing intrauterine device; DVT = deep venous thrombosis; hCG = human chorionic gonadotropin; HIV = human 
immunodeficiency virus; I = initiation of contraceptive method; LNG-IUD = levonorgestrel-releasing intrauterine device; NA = not applicable; 
PE = pulmonary embolism; STI = sexually transmitted infection; VTE = venous thromboembolism.
Source: Modified from CDC. Summary chart of U.S. medical eligibility criteria for contraceptive use. Atlanta, GA: CDC; 2012. (Available at http://www.
cdc.gov/reproductivehealth/UnintendedPregnancy/USMEC.htm.)
* Please see the complete guidance for a clarification to this classification: www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm.
† Condition that exposes a woman to increased risk as a result of unintended pregnancy.
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Contraceptive method
When to start (if the provider is 
reasonably certain that the woman is 
not pregnant)
Additional contraception  
(i.e., back-up) needed
Examinations or tests needed 
before initiation*
Copper-containing IUD Anytime Not needed Bimanual examination and cervical 
inspection†
Levonorgestrel-releasing IUD Anytime If >7 days after menses started, use 
back-up method or abstain for 7 days.
Bimanual examination and cervical 
inspection†
Implant Anytime If >5 days after menses started, use 
back-up method or abstain for 7 days.
None
Injectable Anytime If >7 days after menses started, use 
back-up method or abstain for 7 days.
None
Combined hormonal contraceptive Anytime If >5 days after menses started, use 
back-up method or abstain for 7 days.
Blood pressure measurement
Progestin-only pill Anytime If >5 days after menses started, use 
back-up method or abstain for 2 days.
None
Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; IUD = intrauterine device; STD = sexually transmitted disease; U.S. MEC = U.S. Medical 
Eligibility Criteria for Contraceptive Use, 2010.
* Weight (BMI) measurement is not needed to determine medical eligibility for any methods of contraception because all methods can be used (U.S. MEC 1) or generally 
can be used (U.S. MEC 2) among obese women (Box 2). However, measuring weight and calculating BMI (weight [kg]/height [m]2) at baseline might be helpful for 
monitoring any changes and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method.
† Most women do not require additional STD screening at the time of IUD insertion if they have already been screened according to CDC’s STD Treatment Guidelines 
(available at http://www.cdc.gov/std/treatment). If a woman has not been screened according to guidelines, screening can be performed at the time of IUD insertion, 
and insertion should not be delayed. Women with purulent cervicitis or current chlamydial infection or gonorrhea should not undergo IUD insertion (U.S. MEC 4). 
Women who have a very high individual likelihood of STD exposure (e.g., those with a currently infected partner) generally should not undergo IUD insertion 
(U.S. MEC 3) (Box 2). For these women, IUD insertion should be delayed until appropriate testing and treatment occurs.
Appendix B
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TABLE. Examinations and tests needed before initiation of contraceptive methods
Examination or test
Contraceptive method and class
Cu-IUD and 
LNG-IUD Implant Injectable CHC POP Condom
Diaphragm or  
cervical cap Spermicide
Examination
Blood pressure C C C A* C C C C
Weight (BMI) (weight [kg]/
height [m]2)
—† —† —† —† —† C C C
Clinical breast examination C C C C C C C C
Bimanual examination and 
cervical inspection 
A C C C C C A§ C
Laboratory test
Glucose C C C C C C C C
Lipids C C C C C C C C
Liver enzymes C C C C C C C C
Hemoglobin C C C C C C C C
Thrombogenic mutations C C C C C C C C
Cervical cytology 
(Papanicolaou smear)
C C C C C C C C
STD screening with laboratory 
tests
—¶ C C C C C C C
HIV screening with laboratory 
tests
C C C C C C C C
Abbreviations: BMI = body mass index; CHC = combined hormonal contraceptive; Cu-IUD = copper-containing intrauterine device; DMPA = depot medroxyprogesterone 
acetate; HIV = human immunodeficiency virus; LNG-IUD = levonorgestrel-releasing intrauterine device; POP = progestin-only pill; STD = sexually transmitted disease; 
U.S. MEC = U.S. Medical Eligibility Criteria for Contraceptive Use, 2010.
* In cases in which access to health care might be limited, the blood pressure measurement can be obtained by the woman in a nonclinical setting (e.g., pharmacy 
or fire station) and self-reported to the provider.
† Weight (BMI) measurement is not needed to determine medical eligibility for any methods of contraception because all methods can be used (U.S. MEC 1) or generally 
can be used (U.S. MEC 2) among obese women (Box 2). However, measuring weight and calculating BMI at baseline might be helpful for monitoring any changes 
and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method.
§ A bimanual examination (not cervical inspection) is needed for diaphragm fitting.
¶ Most women do not require additional STD screening at the time of IUD insertion if they have already been screened according to CDC’s STD Treatment Guidelines 
(available at http://www.cdc.gov/std/treatment). If a woman has not been screened according to guidelines, screening can be performed at the time of IUD insertion 
and insertion should not be delayed. Women with purulent cervicitis or current chlamydial infection or gonorrhea should not undergo IUD insertion (U.S. MEC 4). 
Women who have a very high individual likelihood of STD exposure (e.g., those with a currently infected partner) generally should not undergo IUD insertion 
(U.S. MEC 3). For these women, IUD insertion should be delayed until appropriate testing and treatment occurs.  
The examinations or tests noted apply to women who are 
presumed to be healthy. Those with known medical problems 
or other special conditions might need additional examinations 
or tests before being determined to be appropriate candidates 
for a particular method of contraception. The U.S. Medical 
Eligibility Criteria for Contraceptive Use, 2010 (U.S. MEC), 
might be useful in such circumstances (5). The following 
classification was considered useful in differentiating the 
applicability of the various examinations or tests:
Class A: essential and mandatory in all circumstances for 
safe and effective use of the contraceptive method. 
Class B: contributes substantially to safe and effective use, 
but implementation may be considered within the public 
health and/or service context; risk of not performing an 
examination or test should be balanced against the benefits 
of making the contraceptive method available.
Appendix C
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Class C: does not contribute substantially to safe and 
effective use of the contraceptive method.
These classifications focus on the relationship of the 
examinations or tests to safe initiation of a contraceptive 
method. They are not intended to address the appropriateness 
of these examinations or tests in other circumstances. For 
example, some of the examinations or tests that are not deemed 
necessary for safe and effective contraceptive use might be 
appropriate for good preventive health care or for diagnosing 
or assessing suspected medical conditions.  
No examinations or tests are needed before initiating 
condoms or spermicides. A bimanual examination is necessary 
for diaphragm fitting. A bimanual examination and cervical 
inspection are needed for cervical cap fitting.
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TABLE. Routine follow-up after contraceptive initiation
Action
Contraceptive method
Cu-IUD or LNG-IUD Implant Injectable CHC POP
General follow-up
Advise women to return at any time to discuss side effects or other 
problems or if they want to change the method. Advise women 
using IUDs, implants, or injectables when the IUD or implant 
needs to be removed or when a reinjection is needed.  No routine 
follow-up visit is required.
X X X X X
Other routine visits
Assess the woman’s satisfaction with her current method and 
whether she has any concerns about method use.
X X X X X
Assess any changes in health status, including medications, that 
would change the method’s appropriateness for safe and 
effective continued use based on U.S. MEC (i.e., category 3 and 4 
conditions and characteristics) (Box 2).
X X X X X
Consider performing an examination to check for the presence of 
IUD strings.
X — — — —
Consider assessing weight changes and counseling women who 
are concerned about weight change perceived to be associated 
with their contraceptive method.
X X X X X
Measure blood pressure. — — — X —
Abbreviations: CHC = combined hormonal contraceptive; Cu-IUD = copper-containing intrauterine device; HIV = human immunodeficiency virus; IUD = intrauterine 
device; LNG-IUD = levonorgestrel-releasing intrauterine device; POP = progestin-only pill; U.S. MEC = U.S. Medical Eligibility Criteria for Contraceptive Use, 2010.
Appendix D
Routine Follow-Up After Contraceptive Initiation
These recommendations address when routine follow-up 
is recommended for safe and effective continued use of 
contraception for healthy women. The recommendations refer 
to general situations and might vary for different users and 
different situations. Specific populations that might benefit 
from more frequent follow-up visits include adolescents, those 
with certain medical conditions or characteristics, and those 
with multiple medical conditions.
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Appendix E
Management of Women with Bleeding Irregularities While Using Contraception




spotting or light 
bleeding or for heavy 
or prolonged bleeding: 
• NSAIDs  (5–7 days 






spotting or light 
bleeding or heavy/
prolonged bleeding: 
• NSAIDs (5–7 days  
of treatment) 
• Hormonal treatment 
(if medically eligible) 
with COCs or 
estrogen (10–20 days




 spotting or light 
bleeding: 
• NSAIDs (5–7 days 
of treatment) 
For heavy or 
prolonged bleeding: 
• NSAIDs (5–7 days of 
treatment) 
• Hormonal treatment 
(if medically eligible) 
with COCs or estrogen
(10–20 days of 
treatment) 
CHC users (extended or 
continuous regimen)
Hormone-free interval
 for 3–4 consecutive days
Not recommended during 
the rst 21 days of  
extended or continuous 
CHC use
Not recommended more 
than once per month 
because contraceptive 
eectiveness might be 
reduced  
If bleeding disorder persists or woman nds it unacceptable
Counsel on alternative methods and oer another method, if desired.
Abbreviations: CHC = combined hormonal contraceptive; COC = combined oral contraceptive; Cu-IUD = copper-containing intrauterine device; DMPA = depot 
medroxyprogesterone acetate; LNG-IUD = levonorgestrel-releasing intrauterine device; NSAIDs = nonsteroidal antiinflammatory drugs.
* If clinically warranted, evaluate for underlying condition. Treat the condition or refer for care.
† Heavy or prolonged bleeding, either unscheduled or menstrual, is uncommon.
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Appendix F
Management of the IUD when a Cu-IUD or an LNG-IUD User Is Found To Have  
Pelvic Inflammatory Disease
• Treat PID.*
• Counsel about condom use.
• IUD does not need to be removed.
Woman wants to continue IUD. Woman wants to discontinue IUD.
Clinical improvement No clinical improvement • Offer another contraceptive method.
• Offer emergency contraception.
Continue IUD.
Reassess in 24–48 hours. Remove IUD after beginning antibiotics.
• Continue antibiotics.
• Consider removal of IUD.
• Offer another contraceptive method.
• Offer emergency contraception.
Abbreviations: Cu-IUD = copper-containing IUD; IUD = intrauterine device; LNG-IUD = levonorgestrel-releasing IUD; PID = pelvic inflammatory disease.
* Treat according to CDC’s STD Treatment Guidelines (available at http://www.cdc.gov/std/treatment).
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